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Breast cancer is the second leading cause of death due to cancer in
women. A number of effective therapeutic strategies have been implemented
in clinics to cope with the disease yet recurrent disease and toxicity reduce
their effectiveness. Hence, there is a need to identify and develop more effec-
tive therapies with reduced toxic side effects to improve overall survival rates.
This dissertation investigates the mechanisms of action of two natural forms of
vitamin E and a cholesterol lowering drug, simvastatin, as a therapeutic strat-
egy in human breast cancer cells. Vitamin E in nature consists of eight distinct
forms which are fat soluble small lipids. Until recently, vitamin E was known
as a potent antioxidant but emerging work suggests they may be resourceful
agents in managing a number of chronic diseases including cancer. Anticancer
properties of vitamin E have been identified to be limited to the γ- and δ- forms
of both tocopherols and tocotrienols. Gamma-tocopherol (γT) and gamma-
tocotrienol (γT3) have both already been identified to induce death receptor
5 (DR5) mediated apoptosis in breast cancer cells. Studies here show that
similar to γT3, γT induced DR5 activation is mediated by c-Jun N-terminal
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kinase/C/EBP homologous protein (JNK/CHOP) proapoptotic axis which in
part contributed to γT mediated dowregulation of c-FLIP, Bcl-2 and Sur-
vivin. Also, both agents activate de novo ceramide synthesis pathway which
induces JNK/CHOP/DR5 proapoptotic axis and downregulates antiapoptotic
factors FLICE inhibitory protein (c-FLIP), B-cell lymphoma 2 (Bcl-2) and
Survivin leading to apoptosis. Simvastatin (SVA) has been identified to dis-
play pleiotropic effects including anticancer effects but mechanisms responsi-
ble for these actions have yet to be fully understood. In this dissertation, it
was observed that simvastatin induced apoptosis in human breast cancer cells
via activation of JNK/CHOP/DR5 proapoptotic axis and down regulation
of antiapoptotic factors c-FLIP and Survivin which are in part dependent on
JNK/CHOP/DR5 axis. The anticancer effects mediated by simvastatin can be
reversed by exogenously added mevalonate and geranylgeranyl pyrophosphate
(GGPP), implicating the blockage of mevalonate as a key event. Furthermore,
work has been done to understand the factors responsible for drug resistance
and identify therapeutic strategies to counteract the same. It was observed
that development of drug resistance was associated with an increase in the
percentage of tumor initiating cells (TICs) in both tamoxifen and adriamycin
resistant cells compared to their parental counterparts which was accompanied
by an increase in phosphorylated form of Signal transducer and activator of
transcription 3 (Stat3) proteins as well as its downstream mediators c-Myc, cy-
clin D1, Bcl-xL and Survivin. Inhibition of Stat3 demonstrated that Stat3 and
its downstream mediators play an important role in regulation of TICs in drug
resistant breast cancer. Moreover, SVA, γT3 and combination of SVA+γT3
vii
has been observed to target TICs in drug resistant human breast cancer cells
and downregulate Stat3 as well as its downstream mediators making it an at-
tractive agent to overcome drug resistance. From the data presented here, the
mechanisms responsible for the anticancer actions of γT, γT3 and SVA have
been better understood, providing the necessary rationale to test these agents
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Cancer is a leading cause of death among people in the United States.
It is characterized by uncontrolled cellular proliferation and metastasis to dis-
tant sites. Breast cancer is the second largest cause of death in U.S. women
due to cancer. In 2012, 226,870 new cases of breast cancer have been pre-
dicted to be identified in women and claim nearly 39,510 lives [1]. Present
treatment options available to women in the include surgery, radiation ther-
apy, hormonal therapy, chemotherapy and targeted therapy [2]. Often these
options are applied in adjuvant settings to achieve enhanced effects. Yet, these
treatment strategies are limited by their side effects and toxicity [2, 3]. Re-
cently, statins, nutrients and food derivatives have received a lot of attention
as possible preventive and therapeutic agents [4, 5].
1.2 Vitamin E
1.2.1 Structures and forms
Vitamin E is a fat soluble molecule that consists of a phytyl tail and
chroman head. Naturally occurring vitamin E is classified into tocopherols
or tocotrienols based on the degree of saturation of the phytyl tail and abun-
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dantly present in certain plant products such as palm oil, cereal grains, wheat
germ and rice bran. Tocopherols and tocotrienols are further classified into
sub-groups α, β, γ and δ depending on the position of the methyl group on
the chroman head. Furthermore, the synthetic form of vitamin E, (all-rac-α-
tocopherol) and derivatives of vitamin including RRR-α-tocopheryl succinate
(VES) and RRR-α-tocopheryloxyacetic acid also called RRR-α-tocopherol ether-
linked acetic acid analogue (α-TEA) have been investigated for anticancer
properties but they differ from natural forms of vitamin E in their structure
and function [6].
Figure 1.1: Structure of natural source forms of vitamin E.
Natural source vitamin E form are classified as tocopherols or to-
cotrienols based on presence of phytyl tail or isoprenoid tail, respec-
tively. Position of methyl groups in the chroman head determine the
sub-type of tocopherol or tocotrienol.
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1.2.2 Absorption and metabolism
As vitamin E is lipid soluble, its absorption from food or supplements
are dependent on general lipid absorption processes. Vitamin E in food is
emulsified and incorporated into chylomicrons along with other lipids in in-
testinal enterocytes and enters the vascular system via the lymphatic system.
Lipoprotein lipases (LPL) expressed on the surface of many tissues lead to
triglyceride lipolysis delivering vitamin E to the respective tissues along with
other lipids. The chylomicron remnants are absorbed by the hepatic tissues
where they are repackaged into very low density lipoproteins (VLDL) to be
secreted again into the blood [7]. The transfer of vitamin E into VLDL is aided
by -tocopherol transfer protein (α-TTP) which selectively enriches for RRR- α-
tocopherol into the lipoproteins while eliminating the other forms of vitamin E
via bile secretions [8]. Various forms of tocopherols exhibit differential binding
ability with TTP and have been characterized as α > β > γ > δ-tocopherol [7].
Packaged vitamin E can be exchanged between VLDL, low density lipopro-
tein (LDL) and high density lipoprotein (HDL). α-TTP is critical for the
transfer of vitamin E into lipoproteins for tissue distribution. Deficiency of α-
TTP results in reduced absorption of α-tocopherol as demonstrated in α-TTP
knockout (Ttpa-/-) mice fed synthetic all-rac-alpha-tocopherol [9]. In contrast,
tocotrienols were well absorbed by Ttpa-/- mice and distributed to peripheral
tissues even in the absence of α-TTP [9]. Excess vitamin E is eliminated from
the body by metabolism and/or excretion [10]. The phytyl tail is subject
to ω-oxidation by xenobiotic metabolizing enzymes, cytochrome P450 (CYP)
enzymes, followed by several steps of β-oxidation resulting in the formation
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of 2-carboxyethyl-6-hydroxychroman (CEHC) metabolites which accumulate
mostly in the urine [8]. Furthermore, vitamin E itself has been observed to
increase the activity of CYP enzymes, specifically CYP3A and CYP4F2 re-
sulting in tight regulation of vitamin E concentrations [8].
1.2.3 Functions
Classically vitamin E has been identified as an antioxidant. It func-
tions as a peroxyl radical scavenger protecting cellular membranes from lipid-
derived free-radical damage [11]. The antioxidant property of vitamin E has
been widely explored in a number of clinical trials. It has been observed that
vitamin E supplementation can reduce the risk of chronic diseases such as
cardiovascular disorder, artherosclerosis and neurodegenerative diseases [12–
16]. They have also been identified to possess antithrombotic and antiinflam-
matory properties but more unique biological functions have been associated
with tocotrienols [17]. Tocotrienols have been characterized as displaying neu-
roprotective, antiangiogenic, anticancer and cholesterol lowering properties in
addition to modulating immune functions [18] . Hence, gaining a better under-
standing of the functions and interactions of tocotrienols with other nutrients
and drugs is important for development of effective therapeutics.
1.2.4 Anticancer properties of natural forms of vitamin E
Besides understanding the antioxidant properties of RRR- α-tocopherol,
efforts have been made to determine chemopreventive roles. However this has
been unsuccessful to date in pre-clinical animal models and human interven-
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tion studies which have used tumor burden and reduction in cancer risk/ death
respectively as end points. For example, the Alpha-Tocopherol, Beta-Carotene
(ATBC) Cancer Prevention Study examined the effect of 50 mg of all-racemic-
α-tocopheryl-acetate and 20 mg of β-carotene on lung and colorectal cancer in
males [19]. Outcomes included a reduction in risk of colorectal cancer which
was not statistically significant and no effect on lung cancer risk. However, a
reduction in the rate of incidence and death of prostate cancer by 32% and
41%, respectively, was a major factor leading to the design of Selenium and
Vitamin E Cancer Prevention Trial (SELECT) trial to determine the effect of
vitamin E and selenium on prostate cancer. SELECT was a 12 year study in
which male patients were provided dietary supplements consisting of 200 µg
of selenium as L-selenomethionine or 400 IU of synthetic vitamin E as all-rac-
α-tocopheryl acetate or a combination of both agents which was discontinued
early due to lack of beneficial effects [20]. A recently concluded follow-up on
the SELECT study reported a significant increase in prostate cancer risk in
healthy men with vitamin E supplementation compared to healthy men in the
placebo group [21]. A number of case-control and cohort studies have also
examined the role of vitamin E as a chemopreventive agent but the literature
is filled with mixed results from these studies and lack information about the
form of vitamin E. The best example for case-control studies that provided
reliable evidence for anticancer effects of vitamin E is CLUE I and CLUE II
studies in which reduced serum concentration of γ-tocopherol was associated
with increased risk for prostate cancer [22, 23].
At present, cell culture and animal studies demonstrate the importance
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of defining the type of vitamin E studied in cancers and most of the evidence
indicates that anticancer properties are limited to the γ- and δ-tocopherol, and
tocotrienol forms of vitamin E individually or in mixtures enriched in these
forms [6, 24].
1.2.4.1 Mechanisms of action of γ-tocopherol (γT)
Animal studies and cell culture studies have shown gamma-tocopherol
to display more potent anticancer effects than alpha-tocopherol. γT has been
shown to reduce tumor burden as well as lung and lymph node metastases in
syngeneic BALB/c mouse 66cl-4-GFP mammary cancer model whereas RRR-
αT was ineffective [25]. Similarly in a human breast cancer xenograft model
of MDA-MB-231-GFP cells γT was observed to reduce tumor growth and it
was associated with induction of apoptosis studied using TUNEL staining. γT
has been seen to target multiple factors in the process of inducing apoptosis
in various cancer cell lines [26]. In human breast cancer cells, γT induced
apoptosis by enhancing death receptor DR5, inducing activation of caspases-
8 and -9, reduction in protein levels of survival factors c-FLIP and Survivin
[27]. In human prostate cancer γT induced apoptosis via interruption of the
de novo sphingolipid synthesis pathway, release of cytochrome c, activation of
caspases-9,-3 and -7 as well as caspase-independent pathways [28]. In human
colon cells, γT induced apoptosis via activation of caspases-8, -3 and -7 but
not caspase-9 as observed in human breast and prostate cancer cells [29]. A
more complete understanding of the initiating and intermediate events will
help us design more effective combination therapies.
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1.2.4.2 Mechanisms of action of γ-tocotrienol (γT3)
The anticancer effects of tocotrienols have been demonstrated in many
different animal models of cancer [24, 27–29]. Extensive work has also been
carried out using in vitro systems to determine the mechanisms through which
tocotrienols exert their anticancer effects [24]. Unlike tocopherols, only two hu-
man studies have been conducted to date to test the efficacy of tocotrienols in
human subjects. The first study compared the accumulation of various forms
of tocotrienols in the adipose tissue of patients with benign and malignant
tumors consuming a diet rich in palm oil. It was observed that the concen-
tration of tocotrienols was approximately 65% higher in the adipose tissues of
patients with benign tumors compared to patients with malignant tumors [30].
In a recent pilot study conducted by the Malaysian Palm Oil Board, women
with estrogen receptor positive primary tumors were provided a combination
of tocotrienol and tamoxifen for a period of 5 years. Though the study did
not achieve significance, it demonstrated a positive trend towards reduction of
death due to breast cancer and recurrence compared to women provided only
tamoxifen [31].
Tocotrienols similar to tocopherols and other natural agents have been
reported to modulate multiple pathways during apoptosis. In human colon
cancer cells, tocotrienols were observed to enhance TNF-related apoptosis-
inducing ligand (TRAIL) induced apoptosis whereas in human breast cancer
cells tocotrienols induced apoptosis via endoplasmic reticulum stress medi-
ated activation of the death receptor-5 (DR5) pathway [32]. In various other
cancer cells, tocotrienols activated the death receptors DR4 and 5 via reac-
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tive oxygen species (ROS)/ Extracellular signal-regulated kinases (ERK)/p53
pathway [33]. Apoptosis induction also included Transforming growth factor
beta (TGF- β)/ Fas/JNK signaling events, enhanced expression of proapop-
totic Bax and Bid or downregulation of cyclin D1 and Bcl-2 [34, 35]. In ad-
dition to the above studies, tocotrienols have been characterized to induce
cell cycle arrest, suppress transcription factors NF- κB and STAT-3, suppress
hypoxia regulator - HIF-1 α, regulators of oxidative stress, i.e. Nuclear fac-
tor (erythroid-derived 2)-like 2 (Nrf2), angiogeneic factors and growth factor
receptor signaling pathways [36–45]. Accumulating evidence demonstrates to-
cotrienols to be potent anticancer agents that can be combined with present
therapies to enhance their efficacy and reduce toxicity associated side effects.
1.3 Simvastatin
1.3.1 Discovery and health effects
Simvastatin, a synthetic derivative of lovastatin, a fermentation product
from the fungus Aspergillus terreus is a commonly used lipophilic cholesterol
lowering drug. It targets the rate limiting enzyme - 3-hydroxy-3-methylglutaryl
coenzyme-A (HMG-CoA) reductase (HMGCR) in the mevalonate pathway
that ultimately reduces the overall circulating levels of cholesterol [46]. As a
result, statin consumption reduces the risk of cardiovascular disorders. Inhibi-
tion of mevalonate synthesis also leads to inhibition of the synthesis of farne-
syl pyrophosphate (FPP) and geranylgeranyl pyrophosphate (GGPP) that are
important intermediates in cell proliferation and survival [47]. The HMGCR
enzyme is regulated at multiple levels (i.e. transcriptional, translational and
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post-translational) by feedback from both isoprenoids and cholesterol in nor-
mal cells but in tumor cells the enzyme is more sensitive to the isoprenoid feed-
back [48, 49]. This varied response to sterol and non-sterol feedback maybe
responsible for the anticancer effects of statins in tumor cells compared to
immortalized but non-tumorigenic or normal cells [48, 49]. Simvastatin has
been shown to exert anticancer effects in different types of cancer cells in vitro
by inducing apoptosis and reducing tumor growth in pre-clinical xenograft
models of human breast, colon and prostate [50–56]. Human epidemiological
studies have demonstrated long-term use to be associated with reduction in
breast cancer risk and recurrent disease [55, 56]. A number of factors have
been identified to be modulated during induction of apoptosis in breast can-
cer including over-expression of Bax, reduced expression of Bcl-2, generation of
reactive and nitric oxygen species, increased phosphorylation of JNK, suppres-
sion of AKT and nuclear factor kappa B pathway [57–61]. Simvastatin is also
known to modulate the immune system as well as produce anti-inflammatory,
anti-oxidant and anti-angiogeneic effects [62]. Due to these pleiotropic actions
by simvastatin it has gained recognition as an anticancer agent yet its mecha-
nisms of action need to be explored further to gain a better understanding of
its preventive and therapeutic potential.
Despite the pleiotropic health benefits of statin, their application in can-
cer prevention and treatment is reduced by dose limited myotoxicity. Vitamin
E, specifically tocotrienols have been shown to modulate the HMG-CoA re-
ductase enzyme in the mevalonate pathway similar to simvastatin. Tocotrienol
target HMG-CoA reductase enzyme both at the mRNA and protein level by
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Figure 1.2: Mevalonate Pathway.
Products of the mevalonate pathway involve sterol (cholesterol), non-
sterol (farnesol, dolichol, ubiquinone, farnesylated and genranylated
proteins) and isoprenoid products (dimethylallyl pyrophosphate and
isopentenyl purophosphate) which play important roles in cellular
proliferation and survival. (Adapted from [49])
retaining sterol regulatory element binding proteins (SREBP) in the endo-
plasmic reticulum and proteosomal degradation of enzyme respectively [63].
Hence, in tocotrienol treatments negative feedback associated with lowered
cholesterol leading to inhibition of enzyme degradation is ineffective unlike in
statin treatments where lack of simultaneous enzyme degradation enables in-
crease in HMGCR production both at mRNA and protein levels to compensate
for statin induced reduction in enzyme activity [63]. Therefore, a combination
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Figure 1.3: HMG-CoA Reductase feedback control.
The HMG-CoA reductase enzyme is subject to feedback control by
sterol, non-sterol and isoprenoid products. In non-tumor cells, sterol
feedback is the primary mechanism of control whereas in tumor cells,
the elevated levels of HMG-CoA enzyme activity is resistant to sterol
feedback and dependent on non-sterol and isoprenoids metabolites.
(Adapted from [49])
of statin and tocotrienol has been tested for its combined ability to target the
mevalonate pathway in cancer cells at low doses which limit dose associated
toxicity [63]. The combination of γT3 and SVA has been shown to inhibit pro-
liferation and cell cycle arrest in mouse mammary cancer cells. These effects
have been attributed to suppression of MAPK, AKT and cyclin D1 protein
expression levels [63]. The combination of simvastatin and γT3 show promise
as a preventive and therapeutic combination for targeting breast cancer with
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reduced toxic agents which needs to be further explored.
1.4 Apoptosis
Cells in the bodies can undergo four types of cell death, apoptosis, au-
tophagy, cornification and necrosis [64]. Apoptosis is known as programmed
cell death that is responsible for maintenance of cell populations during em-
bryogenesis, development, aging and immune responses. Autophagy has op-
posing roles in the cell, i.e depending on the context of the stimulus it can
activate cell survival or cell death. Necrosis is a toxic form of cell death ac-
companied by inflammatory responses [65, 66]. Unlike necrosis, apoptosis is a
controlled, energy dependent process that does not result in non-specific in-
flammatory responses. Apoptosis is identified by specific morphologic changes
such as cell shrinkage, condensation of cellular contents, DNA fragmentation,
membrane blebbing and formation of distinct apoptotic vesicles [65, 66]. There
are two distinct pathways of apoptosis that can cross-talk with each other:
namely, extrinsic or death receptor mediated pathway or intrinsic mitochon-
dria pathway [67–69]. Both these pathways involve activation of a series of
cysteine-dependent aspartate-directed proteases (caspases) that amplify cel-
lular stress or cell surface receptor activation leading to potent cell death.
These enzymes are usually expressed in inactive forms and require recruit-
ment to adaptor proteins followed by cleavage of the inhibitory prodomains
to be activated [68]. Caspases are organized in a hierarchy as initiator and
executioner caspases. When a cell receives an apoptotic trigger, the initiator
caspases-2, -8, -9, -10 are activated by cleavage which in turn lead to activation
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of effector caspases-3, -6, -7 [70]. Cellular stresses such as radiation, hypoxia
and toxins or absence of growth factors, hormones or cytokines may stimulate
the intrinsic pathway which involves changes in the mitochondrial membrane
permeability and release of two different classes of proteins [65]. The first
group of proteins includes cytochrome c, second mitochondrial derived acti-
vator of caspase/ direct inhibitors of apoptosis (IAP)-Binding protein with
a low pI (Smac/Diablo) and serine protease HtrA2/Omi [71]. Cytochrome c
forms an apoptosome with Apaf-1 and pro-caspase-9 which activates caspase-9
further leading to activation of caspase-3 [72]. Smac/Diablo and HtrA2/Omi
amplify apoptosis by inhibiting activity of inhibitors of apoptosis proteins
[73]. The second group of proteins includes apoptosis inducing factor (AIF),
endonuclease G (EndoG) and caspase-activated-DNase (CAD) [74]. AIF and
EndoG induce DNA fragmentation in a caspase-independent manner whereas
CAD cleaves nuclear DNA following activation by caspase-3 [65, 75, 76]. The
permeability and membrane potential of the mitochondria is controlled and
regulated by members of the Bcl-2 family of proteins [65, 66]. These proteins
are classified as anti- or pro-apoptotic depending on their function. The ratio
of these anti- versus pro-apoptotic members in mitochondria determines cell
fate: survival versus death response to a stimulus. The extrinsic pathway re-
quires binding of ligands such as Fas ligand (FasL), or TNF-related apoptosis-
inducing ligand (TRAIL) to death receptors that are members of the tumor
necrosis factor (TNF) receptor gene superfamily [77, 78]. All TNF receptors
contain a death domain in the cytoplasmic region that transmits the death
signal from the engaged receptor to the cytoplasmic adaptor proteins [79], a
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adaptor proteins Fas-associated death domain (FADD) or tumor necrosis fac-
tor receptor type 1-associated DEATH domain protein (TRADD). FADD and
receptor-interacting protein (RIP) are recruited via their death domains to the
activated receptor that in turn recruits initiator caspase-8 in its inactive form.
This complex is known as the death-inducing signaling complex (DISC) and
results in autocatalytic cleavage of caspase-8 [79]. Executioner caspase-3 is
activated by caspase-8, triggering apoptosis. Similar to the intrinsic pathway,
anti-apoptotic factors also control the response of the cell to a death recep-
tor initiated signal. Cellular FLICE inhibitory protein (c-FLIP) is similar in
structure to caspase-8 with a death domain but lacks catalytic activity. c-FLIP
associates with FADD and pro-caspase-8 in DISC inhibiting the death signal
[65, 66]. The intrinsic and extrinsic pathways of apoptosis can cross-talk to en-
hance the apoptotic cue. Activated caspase-8 cleaves the pro-apoptotic Bcl-2
homology 3 (BH3)-only protein, Bid, that translocates to the mitochondria as
tBid where it can recruit other pro-apoptotic members of the Bcl-2 family of
proteins, Bax and Bak to alter membrane potential and permeability inducing
the intrinsic pathway [65, 66].
1.4.1 TRAIL, Death receptors, CHOP and JNK
Tumour necrosis factor apoptosis inducing ligand (TRAIL) is a trimeric
transmembrane protein that recognizes death receptors DR4 (TRAILR-1),
DR5 (TRICK-2/KILLER/TRAILR-2) as well as decoy receptors (TRAIL-
R3/DcR1 and TRAIL-R3/DcR2) and antagonistic receptor osteoprotegerin/
OPG of the TNF family of receptors via the C-terminal conserved sequence
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[78, 80]. TRAIL can be detected in vesicle-associated forms and in circula-
tion when cleaved by cysteine proteases produced by activated monocytes
and neutrophils. Commonly, interaction of TRAIL with DR4/5 receptors has
been shown to induce apoptosis via recruitment of adaptor proteins FADD
through the death domain (DD) and pro-caspase-8 via the death effector do-
main (DED) forming DISC through interaction of the death domains [79].
Activated capase-8 induces apoptosome formation activating caspase-9 and
eventually effector caspases. In contrast, interaction of TRAIL with DcR1 or
DcR2 does not lead to apoptosis due to their lack of death domain or presence
of truncated death domains, respectively [78]. TRAIL mRNA and protein
has been detected in many human tissues, yet normal tissues of the body are
largely resistant to the apoptotic effects of TRAIL [68]. The differential re-
sponse of normal and tumor tissues to TRAIL induced apoptosis is associated
with the presence of decoy receptors in normal tissues that sequestered TRAIL
away from the death receptors. TRAIL has been observed to be upregulated
during infections in T-cells, dendritic cells, macrophages and natural killer
(NK) cells [68]. It has also been observed to play a role in innate immunity.
However, higher expression of death receptors DR4 and DR5 in transformed
cells makes TRAIL an attractive anti-cancer agent that can specifically target
tumor cells irrespective of their p53 status. Although, recombinant human
TRAIL (rhTRAIL) showed promise in phase I trials, its short half-life in vivo
as well as identification of TRAIL responsive receptors on non-transformed
cells has raised concerns regarding its safety and efficacy [68, 77]. Nonetheless,
more effective variants of TRAIL and agonistic antibodies against TRAIL-
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receptors (DR4 and DR5) are being developed and tested in combination with
chemotherapeutic agents or ionizing radiation in a number of phase I/II trials
which show more potential than TRAIL alone. Despite high expression of
death receptors on tumor cells, treatment with TRAIL has failed to induce
apoptosis in certain tumor cells. A number of theories have been proposed for
the observed resistance. The foremost being the over expression of decoy recep-
tors DcR1/ DcR2 that changes the balance at the cell surface such that tumor
cells remain non-responsive to TRAIL even in the presence of death receptors
DR4 and DR5 [78]. In some cases, defective death receptors with dominant
negative signal inhibition or increased loss/ shedding from cell surface which
result in resistance to TRAIL [81]. Furthermore low levels of death receptors
can contribute to resistance [82]. Apart from the death receptors and their
ligands, resistance has also been attributed to regulators of the apoptotic pro-
cesses. Alteration in caspase-8 activation, elevated expression of inhibitor of
caspase-8, c-FLIP, inhibitors of apoptosis (IAPs), anti-apoptotic Bcl-2 family
members as well as changes in p53 status have all been identified as mecha-
nisms leading to TRAIL resistance [81, 83]. However, therapeutic agents that
enhance death receptors expression and TRAIL responsiveness can be com-
bined with TRAIL to overcome resistance and develop safer strategies [84].
Death receptor, DR5, can be upregulated by multiple transcription factors
such as NF-kB, p53, CCAAT/enhancer binding protein homologous protein/
DNA damage gene 153 (CHOP/GADD153) and kinases that phosphorylate
transcription factors such as JNK [85–90]. DR5 has been shown to be a direct
downstream mediator of p53 induced apoptosis in cells with intact wild-type
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p53 even in the absence of DNA damage. Forced expression of wild-type p53
in p53-null colon cancer cells enhanced DR5 expression levels [90]. NF-kB has
been traditionally observed to upregulate anti-apoptotic factors; however, in
human embryonic kidney cell line 293, it was shown that NF-kB in the pres-
ence of p53, cooperatively binds to the first intronic region in the DR5 gene
promoter to enhance DR5 expression and subsequently induce apoptosis [89].
Pro-apoptotic factor JNK was seen to upregulate DR5 in a CHOP dependent
manner wherein CHOP regulated DR5 expression by binding to 5-region of
the DR5 gene [88]. Agents that regulate the above mentioned upstream me-
diators of DR5 may be useful in enhancing TRAIL responses when used in
combination. CCAAT/enhancer binding protein homologous protein/ DNA
damage gene 153 (CHOP/GADD153) is commonly upregulated during induc-
tion of endoplasmic reticulum stress (ER-stress) [91]. It is a transcription
factor regulated by X-box-binding protein (XBP1), activating transcription
factor 6 (ATF6) and activating transcription factor 4 (ATF4) that bind to cis-
acting elements in the promoter region [92]. CHOP plays a critical role in the
outcome of ER-stress either by reducing cell viability or inducing apoptosis
based on the extent of stress [93, 94]. Multiple genes are regulated by CHOP
including ER oxidase (ERO1) and GADD34 both of which are involved in
ER-stress responses a well as members of the Bcl-2 family of genes such as
anti-apoptotic Bcl-2 and pro-apoptotic Bim [92, 95, 96]. c-Jun N-terminal pro-
tein kinase (JNK) belongs to the mitogen activated protein kinase (MAPK)
superfamily [97]. Three isoforms of JNK have been identified, JNK1, 2 and
3 that arise due to alternate splicing and differential expression [98]. JNK1
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and JNK2 are expressed in most cells whereas JNK3 is expressed specifically
in brain and heart tissues [99]. Activated JNK can regulate transcription
factors c-JUN, ATF-2, Elk-1, p53 and c-Myc as well as members of Bcl-2 fam-
ily such as Bcl-2, Bcl-xL, Bim and BAD. JNK functions both as an anti- or
pro-apoptotic factor and the role is defined by the source, strength and time
period of the stimulus [99]. Hence, JNK plays an important role in survival,
differentiation and apoptosis wherein the cellular context decides the outcome.
1.5 Sphingolipid pathway and ceramide
Sphigolipids are bioactive lipids consisting of a sphingoid backbone,
long-chain fatty acid with an amide link and polar head groups [100]. Vari-
ous types of sphingolipids have been identified such as ceramide, spingomyelin
and glycosphingolipids, which act as second messengers to mediate cellular
proliferation, survival and apoptosis in addition to providing structural sup-
port in the cellular membrane. Ceramide is a second messenger that plays
an important role in growth, differentiation, and apoptosis [100, 101]. It is a
major component of both cell surface and intracellular membranes. Ceramide
is composed of sphingosine, a fatty acid and a hydroxyl head group [102]. Ce-
ramide can be generated in mammalian cells by three different mechanisms:
de novo synthesis, sphingomyelin hydrolysis and a salvage pathway [103]. The
de novo synthesis of ceramide occurs in the endoplasmic reticulum by the con-
densation of precursors serine and palmitoyl-CoA to 3-ketosphinganine which
undergoes further reduction, acylation and oxidation to eventually generate
ceramide [104, 105]. In the sphingomyelin hydrolysis pathway, cermide is gen-
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erated in the membranes by hydrolysis of sphingomyelin by sphingomyelinases
(SMase). Multiple sphingomyelinases have been identified and are charac-
terized by their pH of activity as neutral or acid SMases [106]. In the sal-
vage pathway, glycosphingolipids such as glucosylceramide/lactosylceramide,
sphingosine-1-phosphate or ceramide-1-phosphate are converted to ceramide
at the plasma membrane by cerebrosidase, ceramide synthases and ceramide-1-
phosphate phosphatase, respectively [103]. It has been observed that ceramide
generated by SMases occur within minutes or hours of a stress stimulus whereas
ceramide generated by the de novo pathway provides a sustained ceramide re-
sponse [103]. Various stimuli initiate the de novo and SMase pathways such
as oxidative stress, radiation and death receptors. Ceramide generated in the
endoplasmic reticulum by the de novo synthesis pathway leads to ER-stress
mediated apoptosis. Whereas ceramide generated by SMases causes increased
ceramide accumulation in the membrane which leads to changes in the compo-
sition of membrane domains known as rafts [106]. Ceramide has been shown to
associate with itself to form ceramide-enriched microdomains which can fuse
to generate large ceramide-enriched macrodomains that amplify the primary
death signal, thus triggering apoptosis [106]. Ceramide mediates apoptosis
via suppression of protein kinase zeta-PKC (PKC), Ras, Raf-1, protein phos-
phatases PP1 and PP2A as well as by activation of JNK and induction of
cathepsin D translocation [103]. Manipulation of the ceramide pathways have
been considered for therapeutic purposes since it was observed that trans-
formed cells are more sensitive to ceramide induced apoptosis compared to
normal cells [102]. Hence, strategies that combine ceramide generating agents
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with presently employed clinical agents may prove useful in enhancing thera-
peutic effectiveness while sparing surrounding normal cells.
Figure 1.4: Ceramide synthesis pathways.
Myriocin, fumonisin B1, C8-cyclopropenylceramide (C8CPPC) and
despiramine are well characterized chemical inhibitors of the en-
zymes involved in ceramide synthesis. Ceramide-1-phosphate phos-
phatase (C1P phosphatase); Sphingosine-1-phosphate phosphatase
(S1P phosphatase). (Adapted from [103])
1.6 Cancer stem cells (CSCs) / Tumor initiating cells
(TICs) and drug resistance
Based on the stem cell concept, CSCs / TICs represent a specialized
small population of cells that exist within a tumor that are capable of differen-
tiating into other cells of the tumor, which makes up bulk of the tumor. CSCs/
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TICs in breast cancers have been characterized functionally as being able to
initiate tumors in immune-comprised mice, demonstrate self-renewal measured
in vivo as tumor formation in secondary mice using cells isolated from pri-
mary tumors or in vitro using mammosphere formation assays and differen-
tiate into progeny that constitute the bulk of the tumor [107]. Operationally
TICs have been characterized based on the expression of molecular markers
distinct from the bulk tumor cells such as presence of CD44 (CD44+), absence
of CD24 (CD24-), high aldehyde dehydrogenase activity (ALDH+), CD133+,
PROCR+ and ESA+ [108–111]. Furthermore they display efficient DNA re-
pair mechanisms making them more resistant to radiation or chemotherapy;
epithelial to mesenchymal transition (EMT) leading to enhanced metastasis;
and slow cycling time compared to bulk tumor cells identified by BrdU re-
tention in pulse chase experiments [107, 111–114]. Recently it was observed
that radiation and commonly used chemotherapeutic agents enhance stem cells
populations in vitro, in animal models as well as in tumor tissues isolated from
patients [115–118]. Using paired samples, tumor tissues from patients treated
with neoadjuvant chemotherapy was shown to express higher percentages of
TICs as measured by increase in CD44+/CD24- and ALDH+. Comparison of
gene signatures derived from cells in primary mammospheres cultures with cells
isolated from residual cancers or CD44+/CD24- enriched cells showed that
these populations were enriched for TICs [114, 117, 118]. Several in vitro stud-
ies using established breast cancer cell lines treated with sublethal doses of ra-
diation and chemotherapy provide evidence for resistance of these populations
to common clinical therapies. Resistance has been associated with increased
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expression of Wnt, Notch, Hedgehog, Her-2/PI3K/AKT, PI3K/mTOR/Stat3,
DNA repair response proteins (CHK1, CHK2) or ATP-binding cassette (ABC)
multidrug efflux transporters among others [107, 113, 119]. Hence, there is a
need to develop therapeutic strategies targeting TICs to reduce recurrent dis-
ease and improve overall survival rates while ensuring normal cells remain
uncompromised. A number of synthetic agents that target growth factor sig-
naling and survival pathways are being tested for their ability to target TICs
such as Her-2 monoclonal antibody (herceptin), EGFR/Her-2 inhibitor (la-
patinib), BCR-ABL kinase inhibitor (imatinib) and telomerase inhibitors in
clinics but there is also a need to develop less toxic therapies as anti-TIC
therapies [113].
1.7 Stat3, stem cells and drug resistance
Signal transducers and activators of transcription (Stat) is a family
of transcription factors that are activated by interferon receptors during cy-
tokine signaling. At present seven Stat proteins have been identified which
can be activated by cytokines (IFN α, IL-6, IL-12, IL-13) and growth fac-
tors (EGF, PDGF, insulin, IGF-1 and more) [120]. Stat3, a widely studied
form of Stat in tumors, has been shown to be highly expressed in most malig-
nant tissues compared to the non-malignant surrounding cells in breast cancer,
prostate cancer, head and neck squamous cell carcinoma, multiple myeloma,
lymphomas and leukemia, brain tumors, colon cancer, Ewing sarcoma, gas-
tric cancer, esophageal cancer, ovarian cancer, nasopharyngeal cancer, and
pancreatic cancer [121]. Stat3 signaling can be activated by oxidative stress,
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Figure 1.5: TIC vs Non-TIC treatment effects.
Conventional therapies target the non-TIC populations resulting in
residual TICs that can differentiate to lead to treatment resistance
and tumor relapse whereas treatments targeting both TIC and non-
TIC would be more effective in providing cures. (Adapted from [119])
tobacco chewing, hepatitis C virus, ultraviolet B, lipopolysaccharide, osmotic
shock, and progestins in addition to the cytokine and growth receptors [121].
Activation of Stat involves phosphorylation of the 705 tyrosine residue at the
C-terminal domain which leads to formation of homo- or heterodimers that
translocates to the nucleus and bind via DNA-binding domains upstream of
the promoter region of the regulated genes [120]. Stat3 plays an important role
in both developmental stages and progression of tumors via modulation of cell
proliferation, apoptosis, angiogenesis, and immune system evasion. Well de-
fined downstream mediators of Stat3 are Mcl-1, Bcl-xL and Survivin that act
as anti-apoptotic factors; c-Myc and CyclinD1 that regulate cell proliferation;
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Figure 1.6: Anti-TIC treatments.
Ligands (blue arrows) bind to receptors activating TIC pathway that
are important for maintenance of TICs. Chemical and DNA in-
hibitors (orange) that block activation of these pathways at various
stages have been developed for clinical purposes. (Adapted from
[113])
matrix metalloproteinase-9 (MMP-9) that mediates invasion; and vascular en-
dothelial growth factor (VEGF) that regulates angiogenesis [120, 121]. Stat3
has been also been reported to be responsible for drug resistance and mainte-
nance of stem cells [122, 123]. Hence, agents that target Stat3 may prove to be
potent preventive and therapeutic agents to reduce resistance and recurrence,
thereby improving survival outcomes.
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1.8 Specific aims and objectives
Vitamin E and its antioxidant properties have been known for many
years; but its role in prevention and treatment of chronic diseases including
cancer is just coming to light. A review of the literature shows there is a large
gap in the knowledge about vitamin E in general and about its anticancer
potential in particular. Both γT and γT3 have been shown to induce apopto-
sis and reduce/ slow down tumor growth in different types of cancer both in
syngeneic and xenograft animal models; inhibit proliferation but their clinical
application is severely limited by their metabolism which reduces their in vivo
availability. Moreover recently, γT3 has been shown to inhibit self-renewal of
TICs and prevent tumor formation [124]. Work also shows that γT and γT3
regulate HMG-CoA reductase enzyme, the rate limiting enzyme in the meval-
onate pathway. Statins have been prescribed for many years as cholesterol
lowering drugs and target the mevalonate pathway. Though statins have also
been demonstrated to display anticancer effects, not much is known about its
mechanisms of actions. Hence, there is a need to improve our basic understand-
ing of the mechanisms of action of naturally occurring forms of vitamin E and
the commonly used clinical agent, statins such that they might be combined
to yield better efficacy and fewer toxic side effects in prevention and treatment
of cancer. Studies in this dissertation are focused on the following aspects: 1)
To identify the anticancer mechanisms of simvastatin, a commonly prescribed
cholesterol lowering drug; 2) To obtain a more complete understanding of the
anticancer mechanisms of γT that is commonly found in the US diet and iden-
tify the events common to both γT and γT3 induced apoptosis; 3) To identify
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the contributing factors in drug resistance development and identify a possi-
ble therapeutic strategy to address drug resistance. This chapter 1 provided
a brief review of the literature and background information on the various
agents investigated. Chapter 2 describes the role of death receptor, DR5, and
its upstream mediators in simvastatin-induced apoptosis and downregulation
of antiapoptotic factors in human breast cancer cells. Chapter 3 is focused
on gaining a better understanding of the upstream mediators of apoptosis in
γT induced apoptosis. The effect of both γT and γT3 on de novo ceramide
pathway will also be described. Chapter 4 determines key factors associated
with drug resistance and addresses the contribution of Stat3 pathway to the
same. Chapter 5 summarizes the present work and describes future directions
for research in these areas.
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Chapter 2
Simvastatin induces apoptosis of human breast
cancer cells via activation of
JNK/CHOP/DR5 and suppression of
c-FLIP/Survivin
2.1 Abstract
Simvastatin-induction of apoptosis in a dose-dependent fashion in hu-
man breast cancer cell lines was shown to involve (i) enhanced expression of
death receptor-5 (DR5), CCAAT/enhancer binding protein (C/EBP) homol-
ogous protein (CHOP), and phosphorylated c-Jun N-terminal kinase (pJNK),
and (ii) decreased levels of anti-apoptotic mediators c-FLIP (cellular-FADD-
like IL-1alpha-converting enzyme inhibitory protein) and survivin. The nec-
essary involvement of these pro-apoptotic and anti-apoptotic mediators was
demonstrated by siRNA knockdown studies. siRNA knockdown of DR5, CHOP
or JNK significantly decreased the ability of simvastatin to induce apoptosis
and showed the necessity of a JNK/CHOP/DR5 amplification signaling path-
way in simvastatin induced apoptosis. Moreover, siRNA knockdown studies
showed that down-regulation of two key anti-apoptotic mediators, c-FLIP and
survivin, was mediated by JNK/CHOP/DR5. Activation of JNK/CHOP/DR5
pro-apoptotic pathway and suppression of c-FLIP and survivin anti-apoptotic
factors by simvastatin was shown to be dependent on simvastatin’s known
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property to block 3-hydroxy-3-methylglutaryl Coenzyme A (HMG-CoA) re-
ductase, the rate-limiting enzyme in cholesterol synthesis. Exogeneous addi-
tion of either mevalonate or geranylgeranyl pyrophosphate (GGPP), but not
farnesylpyrophosphate (FPP) or cholesterol inhibited simvastatin activation
of JNK/CHOP/DR5 apoptotic pathway as well as inhibited down-regulation
of anti-apoptotic mediators c-FLIP and survivin.
2.2 Introduction
Breast cancer incidence and death remains a major health concern
for women [1]. Systemic treatments, including cytotoxic, hormonal, and im-
munotherapeutic agents, are effective initially in 90% of primary breast cancers
and 50% of metastases; however, after variable periods of time drug resistance
and toxicity limit treatment effectiveness [3, 125, 126], highlighting the need
for new treatment regimens.
Statins are widely prescribed drugs used for the reduction of cholesterol
levels via inhibition of 3-hydroxy-3-methylglutaryl Coenzyme A (HMG-CoA)
reductase, the enzyme that catalyses the rate-limiting step in mevalonate syn-
thesis. This pathway is critical for the cellular synthesis of cholesterol and
its isoprenoid intermediates; such as, geranylgeranyl pyrophosphate (GGPP)
and farnesylpyrophosphate (FPP). These mevalonate-derived prenyl groups
exert pleiotropic effects on many essential cellular functions including cell
proliferation, differentiation, and survival [127–129]. In vitro and preclinical
studies as well as clinical studies have shown that various statins, particu-
larly lipophilic statins, have antiproliferative, antiangiogenic, antimetastasis
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and pro-apoptotic properties in many types of cancers including breast cancer
[130, 131].
Simvastatin (SVA) is a commonly used lipophilic statin derived from
lovastatin. SVA shows antitumor actions in vitro and in pre-clinical xenograft
models of breast, colon and prostate as well as efficiacy as a chemopreventive
agent in reducing the risk of breast cancer in humans with long-term use [50–
55]. The ability of SVA to induce apoptosis in breast cancer cells is established
and several insights into SVA’s mechanisms-of-action in the induction of apop-
tosis have been gained [57–61]. Proposed mechanisms that contribute to SVA
induced apoptosis in human breast cancer cells include: JNK phosphorylation
[57], generation of reactive oxygen species [58], activation of inducible nitric
oxygen species resulting in increase of nitric oxide [59], suppression of Akt
[60] and suppression of NF-kB [61]. Despite this knowledge, a more complete
understanding of SVA induced apoptosis is needed in order to improve SVA
treatments by pairing SVA with agents that can act in an additive or syner-
gistic manner. Here, for the first time, we show that SVA induces apoptosis in
human breast cancer cells via activation of a death receptor DR5 pro-apoptotic
pathway and suppression of c-FLIP and survivin, in a JNK/CHOP dependent
manner which is subject to blockage by exogenously added mevalonate and
geranylgeranylpyrophosphate.
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2.3 Materials and Methods
2.3.1 Chemicals
Simvastatin sodium salt (SVA), an active form of simvastatin for in vivo
use, was obtained from Calbiochem (San Diego, CA). Mevalonate (Me), ger-
anylgeranyl pyrophosphate (GGPP) and farnesylpyrophosphate (FPP) were
obtained from Sigma (St. Louis, MO).
2.3.2 Cell Culture
Human breast cancer cell lines; MDA-MB-231 [American Type Culture
Collection (ATCC), Manassas, VA], MCF-7 (ATCC), SUM 159 (Asterand,
Detroit, MI), acquired tamoxifen resistant MCF-7 (MCF-7/TamR, gift from
Dr. Linda deGraffenried, University of Texas at Austin, Austin, TX), and ac-
quired doxorubicin resistant MCF-7 (MCF-7/ADR, gift from Dr. Kapil Mehta,
M.D. Anderson Cancer Center, Houston TX), human ovarian cancer cell line;
A2780 (ATCC), human prostate cancer cell line; LNCap-GFP [LNCap cells
stably transfected with green fluorescent protein (GFP), gift from Dr. LuZhe
Sun, University of Texas Health Science Center at San Antonio, San Antonio,
TX], immortalized non-cancerous human epithelia breast cell line; MCF-10A
(ATCC) and human umbilical vein endothelial cells (HUVEC) (ATCC) were
used in this study. SUM159 cells were cultured in Hams F12 medium (Invit-
rogen, Carlsbad, CA) with 5% fetal bovine serum, 5 µg/ml insulin, 1µg/ml
hydrocortisone (Sigma-Aldrich, St Louis, MO), and 10 mM HEPES buffer.
MCF-7/TamR and MCF-7/ADR cells were derived from the parental cell lines
by selection with tamoxifen and doxorubicin [132, 133], respectively. MCF-
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7/TamR cells were maintained in modified IMEM (Invitrogen, Carlsbad, CA)
supplemented with 10% charcoal stripped bovine serum (Invitrogen, Carls-
bad, CA), 2 mM glutamine, 100 U/ml penicillin, 100 mg/ml streptomycin,
1 × MEM non-essential amino acid solution (Sigma-Aldrich, St Louis, MO),
2 × MEM vitamins solution (Sigma-Aldrich, St Louis, MO) and 100 nM ta-
moxifen (Calbiochem, Gibbstown, NJ). MCF-7/ADR cells were maintained in
RPMI 1640 supplemented with 10% fetal bovine serum, 2 mM glutamine, 100
U/ml penicillin, 100 mg/ml streptomycin and selected every three passages
with 1g/mL of doxorubicin. HUVEC were cultured in endothelial cell basal
medium with growth supplements (EGM-2 Bullet Kit, Clonetics). MCF-10A,
A2780, and LNCap cells were cultured as described previously by Yu W et
al., [134], Jia L et al., [135] and Sun M et al., [136], respectively. To mimic
the non-serum condition of tumors, studies were conducted with 2% serum.
Cells were plated at 3 x 105 cells/100 mm dish or 6 x 105/150 mm dish for
apoptosis and western blot analyses, respectively. Cells were allowed to attach
overnight before treatments. SVA dissolved in ethanol at 20 mM was used as
stock solution. Equivalent levels of ethanol were used as vehicle control (VEH)
for experiments.
2.3.3 Quantification of apoptosis
Apoptosis was quantified using an Annexin V-FITC/PI assay (Indra
Mahajan, Bratton Lab, UT-Austin, TX) as described previously [32, 137]. An-
nexin V-FITC/PI assay measures the amount of phosphatidylserine on the
outer surface of the plasma membrane (a biochemical alteration unique to
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membranes of apoptotic cells) and amount of propidium iodide (PI), a dye
that does not cross the plasma membrane of viable cells but readily enters
dead cells or cells in the late stages of apoptosis and binds DNA. Fluores-
ence was measured using Fluorescence Activated Cell Sorter (FACS) analyses
with a FACSCalibur flow cytometer and data were analyzed using CellQuest
software (BD Biosciences, San Jose, CA). Cells displaying phosphatidylserine
on their surface (positive for annexin-V fluorescence) were considered to be
apoptotic.
2.3.4 Western blot analyses
Preparation of whole cell protein extracts and western blot analyses
were conducted as described previously [32, 137]. Protein bands were imaged
and quantified after correcting for GAPDH loading control using Scion Im-
age Software (Scion Corporation, Frederick, MD). Primary antibodies used
in this study were; pJNK, total JNK, CHOP, c-FLIP and survivin (Santa
Cruz Biotechnology, Santa Cruz, CA), DR5, Caspase-8 and Caspase-9 (Cell
Signaling) and glyceraldehyde-3-phosphate dehydrogenase (GAPDH, made in
house). Secondary antibodies used included: horseradish peroxidase conju-
gated goat-anti-rabbit and rabbit-anti-mouse (Jackson Immunoresearch, Rock-
ford, IL).
2.3.5 Small interfering RNA (siRNA) transfection
A scrambled RNA duplex that does not target any known genes was
used as the nonspecific negative control for RNAi (referred to as control
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siRNA). Transfection of siRNAs to JNK2/1, CHOP, DR5 and Itch or con-
trol (Ambion, Austin, TX) was performed in 100 mm2 cell culture dishes at
a density of 2 × 106 cells/dish using Lipofectamine-2000 and siRNA duplex,
resulting in a final siRNA concentration of 30 nM following the company’s in-
structions. One day after transfection, the cells were re-cultured in 100 mm2
dishes at 5× 105 cells/dish and incubated for 1 day followed by treatments.
2.3.6 Statistical Analyses
The students t-test was used to determine statistical differences be-
tween treatment and control values. Differences were considered statistical
significant at p < 0.05.
2.4 Results
2.4.1 SVA induces human breast cancer cells to undergo apoptosis
SVA treatment of MDA-MB-231 and MCF 7 cells for 3 days at 0.625,
1.25 and 2.5, and 1.25, 2.5 and 5 µM, respectively, significantly induced apop-
tosis in both cell lines in a dose response manner (Fig 2.1 A & B) where doses
up to 2µM are achievable in humans [138].
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Figure 2.1: SVA induced dose-dependent apoptosis in MDA-MB-
231 and MCF-7 human breast cancer cells. MDA-MB-231 and MCF-
7 cells were treated with SVA for 3 days with 0.625, 1.25, and 2.5 and
1.25, 2.5 and 5.0 µM, respectively. Apoptosis was determined by An-
nexin V/FACS analyses (A & B). Western blot analyses were carried
out to detect cleavage of PARP, caspase-8 and caspase-9 (C). A and B
data are depicted as mean ± S.D. of three independent experiments.
C data are representative of two or more independent experiments.
*Significantly increased in comparison to vehicle (VEH), P < 0.05.
Based on EC50 values, the sensitivity of breast cancer cell lines to SVA
induced apoptosis was shown to differ. MDA-MB-231 cells with an EC50 value
of 2.5 were more sensitive to SVA-induced apoptosis than MCF-7 or SUM 159
breast cancer cell lines with EC50 values of 5.0 and 3.3, respectively (Table
2.1). Unexpectedly, data showed MCF-7/TamR and MCF-7/ADR resistant
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cell lines to be more sensitive to SVA induced apoptosis than MCF-7 cells, with
EC50 values of 1.5 and 1.6 µM, respectively (Table 2.1). These data suggest
that SVA can be used as a treatment for chemotherapy resistant breast cancers
by itself or in combination with other agents which will lower the effective
doses of SVA required for treatment. Furthermore, data show that MCF-
10A, an immortalized non-cancerous human epithelial breast cell line, is more
resistant to SVA with EC-50 value > 20µM (Table 2.1), suggesting that SVA’s
apoptotic property is not observed in non-cancerous human epithelial breast
cells. Western blot analyses of whole cell extracts from SVA-treated MDA-MB-
231 and MCF-7 cells show SVA to induce dose-dependent PARP cleavage,
a marker for caspase dependent apoptosis, and caspase-8 and -9 cleavage,
biochemical indicators of caspase activation (Fig 2.1C). These data further
confirm the pro-apoptotic properties of SVA, and show that SVA induced
apoptosis is associated with caspase-8 activation, suggesting involvement of
death receptor-mediated apoptotic pathways.
2.4.2 SVA-induced apoptosis is associated with enhanced DR5 pro-
tein expression
MDA-MB-231 and MCF-7 cells treated with different levels of SVA for
3 days showed increased levels of DR5 (L/S) protein (Fig 2.2 A) in comparison
to vehicle control. We tested the generality of SVA in MCF-7/ADR, SUM 159
and MCF-7/TamR cell lines and showed that treatment with 0.625 µM SVA
for 3 days enhanced DR5 (L/S) protein levels in all three cell lines (Fig 2.2 B).
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Cell Types EC50 of apoptosis (µM)
MDA-MB-231 2.72 ± 0.21
MCF-7 6 ± 1
MCF-7/TamR 0.8 ± 0.2
MCF-7/ADR 0.76 ± 0.25
SUM159 4 ± 0.62
MCF-10A > 20
Table 2.1: Determine sensitivity of breast cancer cell lines to SVA-
induced apoptosis.Breast cancer cell lines and immortalized non-
cancerous human epithelia breast cell line MCF-10A were treated
with 0.625, 1.25, 2.5, 5, 10 and 20 µM SVA for three days.EC50
apoptotic values for SVA treatment of breast cancer cell lines were
determined by Annexin V/FACS analyses. Data are presented as
mean ± S.D. of three individual experiments.
2.4.3 SVA up-regulates CHOP and pJNK
Since pJNK and CHOP has been shown to act upstream in the acti-
vation of DR5 (L/S) [21-22], studies were conducted to determine effects on
SVA treatment on pJNK and CHOP protein expression. SVA treatment of
MDA-MB-231 and MCF-7 breast cancer cells for three days increased pJNK
and CHOP protein expression in both cell lines in a dose-dependent manner
in comparison with VEH (Fig 2.3A and B).
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Figure 2.2: DR5 (L/S) is upregulated in SVA induced apoptosis.
MDA-MB-231 and MCF-7 cells were cultured with three concen-
trations of SVA for 3 days (A). MCF-7/ADR, SUM159, and MCF-
7/TamR cell lines were cultured with 0.625 µM SVA for 3 days (B).
Western blot analyses were performed to evaluate DR5 (L/S) pro-
tein levels (A and B). A and B data are representative of two or more
independent experiments.
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Figure 2.3: CHOP and pJNK is upregulated in SVA induced
apoptosis.MDA-MB-231 and MCF-7 cells were treated with 0.625,
1.25 and 2.5, 1.25, 2.5 and 5 µM, SVA, respectively, for 3 days.
Western blot analyses were performed to evaluate CHOP protein
levels (A)and pJNK 2/1 and total JNK (t-JNK2/1) protein levels
(B). A and B data are representative of two or more independent
experiments.
2.4.4 SVA up-regulation of CHOP and DR5(L/S) and apoptosis is
JNK2 dependent
siRNA to JNK2, CHOP and DR5 significantly reduced the ability of
SVA to induce apoptosis in both cell lines as measured by Annexin V (Fig
2.4A) and PARP cleavage analyses (Fig 2.4B). siRNA to JNK2, CHOP and
DR5 significantly reduced the ability of SVA to induce apoptosis in MDA-
MB-231 and MCF-7 cell lines in comparison to control siRNA (Fig 2.2 C),
and reduced the ability of SVA to induce apoptosis as measured by cleavage
of PARP, and reduced the ability of SVA to increase pJNK, CHOP and DR5
(L/S) protein levels (Fig 2.2B). These data confirm that JNK2 is involved in
SVA induced apoptosis.
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Figure 2.4: SVA induced increase in CHOP and DR5 proteins and
apoptosis are JNK dependent.MDA-MB-231 and MCF-7 cells were
transiently transfected with siRNA to JNK, CHOP and DR5 using
non-specific siRNA as negative control followed by treatment with
2.5 and 5 µM SVA respectively for 3 days. Apoptosis was determined
by Annexin V/FACS analyses (A and B). Western blot analyses were
performed to evaluate PARP cleavage, pJNK 2/1, CHOP, and DR5
(L/S) protein levels using GAPDH as loading control in both cell
lines (C). C data are representative of two or more independent ex-
periments. A and B data are presented as the mean ± S.D. of three
independent experiments. *significantly reduced in comparison to
cells cultured with SVA plus control siRNA, P < 0.05.
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Furthermore, siRNA to JNK blocked the ability of SVA to increase
CHOP and DR5 (L/S) protein levels(Fig 2.4C). These data show that SVA
induced increased CHOP and DR5 protein levels are down stream of JNK2/1.
2.4.5 SVA decreased levels of anti-apoptotic factors c-FLIP (L) and
survivin are regulated by JNK/CHOP
Treatment of MDA-MB-231 and MCF-7 cells with different levels of
SVA for 3 days reduced c-FLIP (L) and survivin protein levels in a dose-
dependent manner with GAPDH as loading control (Fig 2.5A, top panels 1 &
2). c-FLIP mRNA was not markedly regulated by SVA (Fig 2.5A, panel 4).
Survivin mRNA levels were downregulated by SVA only at the higher concen-
trations of SVA (Fig 2.5A, panel 5). These data suggest that SVA downregula-
tion of c-FLIP is mainly regulated at the protein level while downregulation of
survivin may involve both transcriptional and post-transcriptional processes.
Furthermore, siRNA knockdown of JNK or CHOP prevented the ability of
SVA to reduce c-FLIP (L) and survivin protein expression partially in both
cell lines (Fig 2.5B).
2.4.6 SVA down-regulation of anti-apoptotic factor c-FLIP (L) is
integral to SVA mediated apoptosis
Since c-FLIP (L) plays an important role in inhibiting apoptosis, we
hypothesized that SVA mediated downregulation of c-FLIP may play a critical
role in SVA induced apoptotic events. Furthermore, c-FLIP (L) protein levels
have been reported to be regulated by JNK via E3 ubiquitin ligase Itch [139].
Studies were carried out to determine if SVA mediated down-regulation of c-
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Figure 2.5: c-FLIP (L) and survivin are downregulated by SVA
via JNK and CHOP dependent manner where JNK induced down-
regulation of c-FLIP is mediated by Itch. MDA-MB-231 and MCF-7
cells were treated with three doses of SVA for 3 days. Western blot
analyses were performed to evaluate c-FLIP (L) and survivin protein
(A, panels 1 & 2) and mRNA levels (A, panels 4 & 5)). GAPDH
and β-active served as load lane controls (A). MDA-MB-231 and
MCF-7 cells were transiently transfected with JNK or CHOP siR-
NAs or control siRNA followed by treatment with 2.5 and 5 µM
SVA, respectively for 3 days. c-FLIP (L) and survivin protein levels
were determined by western blot (B). MDA-MB-231 cells transiently
transfected with control or Itch siRNA were cultured with 2.5 µM
SVA for 3 days. Apoptosis was determined by Annexin V/FACS
analyses (C); western blot analyses were conducted to determine
cleaved PARP and c-FLIP (L) protein levels using GAPDH as load-
ing control (D). A, B and D data are representative of two or more
independent experiments. C data are presented as the mean ± S.D.
of three independent experiments. Numbers in A, B, and D data
were generated by densitometric analyses *significantly reduced in
comparison to cells cultured with SVA plus control siRNA, P < 0.05
.
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FLIP (L) was regulated by Itch and required for apoptosis. MDA-MB-231 cells
transfected with scrambled control and Itch siRNA were treated with 2.5 µM
SVA. siRNA knockdown of Itch significantly blocked SVA induced apoptosis
as seen by Annexin V (Fig 5C) and cleaved-PARP analyses (Fig 2.5D), and
SVA mediated downregulation of c-FLIP (L) protein levels (Fig 2.5D). These
data indicate that SVA induced downregulation of c-FLIP (L) protein levels
are regulated by Itch and involved in SVA mediated apoptosis.
2.4.7 SVA activation of JNK/CHOP/DR5 pro-apoptotic pathway
and suppression of c-FLIP and survivin anti-apoptotic factors
are blocked by addition of exogenous mevalonate or GGPP,
but not FPP
To determine if SVA induced activation of JNK/CHOP/DR5 pro-apoptotic
pathway and suppression of c-FLIP and survivin anti-apoptotic factors were
regulated by SVA blockage of mevalonate pathway products namely, meval-
onate (Me), GGPP or FPP, MDA-MB-231 and MCF-7 cells were cultured for
two days with 10 µM GGPP or FPP or 1 mM Me with or without 2.5 and 5
µM SVA, respectively. Adding GGPP or Me significantly reduced the ability
of SVA to induce apoptosis as determined by annexin V (Fig 2.6 A) and PARP
cleavage analyses (Fig 2.6 C). Furthermore, both GGPP and Me blocked the
ability of SVA to activate caspases 8 and 9, to up-regulate pJNK 2/1, CHOP
and DR5 (L/S) protein levels and to down-regulate c-FLIP (L) and survivin
(Fig 2.6 C). Treatment of MDA-MB-231 and MCF-7 cells with SVA in the
presence of FPP had no effect on SVA induced events (Fig 2.6 B and D). In
addition, exogenous cholesterol did not block SVA induced apoptosis (data not
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shown). These data show that SVA-induced pro- and anti-apoptotic events are
mediated via inhibition of mevalonate and GGPP and are independent of FPP
and cholesterol.
43
Figure 2.6: Exogenous mevalonate and GGPP (but not FPP)
blocked SVA induced apoptosis, upregulation of JNK/CHOP/DR5
and downregulation of c-FLIP and survivin protein levels. MDA-
MB-231 and MCF-7 cells were pre-treated with mevalonate (Me) (1
mM), GGPP (10 µM) or FPP (10 µM) for 2 hrs followed by treat-
ment with 2.5 and 5 µM SVA, respectively for 3 days. Apoptosis was
evaluated by annexin V assay (A and B). Cleaved PARP (c-PARP),
casapses-8 and 9, pJNK 2/1, CHOP, DR5 (L/S), c-FLIP (L) and
survivin protein levels were determined by western blot analyses (C,
F). A and B data are presented as the mean ± S.D. of three inde-
pendent experiments. * and ** significantly reduced in comparison
to cells cultured with SVA only in MDA-MB-231 and MCF-7 cells
respectively, P < 0.05. C and D data are representative of two or
more independent experiments.
2.4.8 Simvastatin mediated apoptotic events are not limited to
breast cancer cells
To determine if SVA mediated activation of DR5 and CHOP, and sup-
pression of c-FLIP and Survivin are applicable to other cell types, human
umbilical vein endothelial cells (HUVEC) (Fig 2.7A), A2780 human ovarian
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Figure 2.7: Effect of SVA treatment on MCF-10A, HUVEC, A2780
and LNCap cells. Immortalized non-cancerous human epithelia
breast cell line, MCF-10A and human umbilical vein endothelial
cells (HUVEC)(A), as well as A2780 human ovarian cancer cells and
LNCaP human prostate cancer cells (B) were treated with SVA with
or without mevalonate (Me) (1 mM) for 3 days followed by western
blot analyses to determine the protein expressions of CHOP, DR5,
c-FLIP and Survivin. Data are representative of two independent
experiments.
cancer cells and LNCaP human prostate cancer cells (Fig 2.7B) were treated
with SVA for three days with or without mevalonate. Data show that SVA
induced upregulation of DR5 and CHOP protein expression, and downreg-
ulation of anti-apoptotic factors c-FLIP and Survivin protein expression are
common to HUVEC and other cancer cells which can be reversed in the pres-
ence of mevalonate. Furthermore, treatment of immortalized non–cancerous
human epithelia breast cell line, MCF-10A with SVA showed that SVA medi-
ated events were restricted to non-cancerous breast cells.
Based on data presented in this paper, a diagram of signaling events
involved in SVA induction of apoptosis of human breast cancer cell lines is
provided in Figure 2.8. SVA blocks production of mevalonate and GGPP,
resulting in activation of JNK2/1. pJNK2/1 downregulates anti-apoptotic
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Figure 2.8: Proposed signaling pathways whereby SVA induces hu-
man breast cancer cells to undergo apoptosis. SVA inhibits meval-
onate/GGPP pathway by blocking HMG-CoA reductase. This initial
blockage leads to activation of JNK (pJNK2/1), pJNK2/1 induces
increased levels of CHOP leading to DR5 amplification. pJNK2/1
inhibition of anti-apoptotic c-FLIP (L) promotes caspase-8 medi-
ated pro-apoptotic cascade, and survivin down-regulation via CHOP
enhances caspase-9 mediated apoptosis. These combined events
lead to DR5 mediated caspase-8 cleavage and activation, leading to
mitochondria/caspase-9 mediated apoptotic cascade.
46
factor c-FLIP and activate CHOP which produces both a decrease in anti-
apoptotic factor survivin and increase in DR5 expression. The combination
of decreased survival factors and increased DR5 produces increased tumor cell
death.
2.5 Discussion
Although considerable progress has been made in understanding the
anti-cancer actions of statins using tumor cells in culture and although in
vivo anti-tumor efficacy of statins have been validated using xenograft mod-
els, important information about critical events in statin-induced apoptosis in
cancer cells and effects on tumors remain unclear. Here, for the first time,
studies demonstrate that simvastatin, a member of the statin family, induces
apoptosis in human breast cancer cell lines via activation of DR5 death recep-
tor events and suppression of anti-apoptotic factors c-FLIP and survivin via
JNK/CHOP-dependent events which can be reversed by some but not all by-
products of the mevalonate pathway for the biosynthesis of cholesterol. This
new knowledge suggests that increases in protein levels of DR5 and CHOP
which would be detectable by immunohistochemistry in tumor biopsied mate-
rial may serve as useful biomarkers to assess patient tumor responsiveness to
SVA treatment.
Novel findings in this paper are that SVA: (i) induces death receptor
DR5 dependent apoptosis via up-regulation of DR5 protein expression (ii)
induces up-regulation of CHOP protein levels via a JNK dependent event, and
(iii) up-regulates DR5 and suppresses c-FLIP and survivin via JNK/CHOP-
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dependent event. These data provide new insights into the anticancer actions
of SVA, and provide information on potential biomarkers to be used in science-
based decision making regarding the use of SVA in the treatment of cancer.
Data, for the first time, show that DR5 protein is up-regulated by SVA
and involved in SVA induced apoptosis. Previous studies have shown that DR5
can be up-regulated by NF-kB [86, 87], p53 [87], JNK [32, 88, 137] and CHOP
[32, 88, 137]. Data presented here show that SVA mediated up-regulation of
DR5 is due at least in part to both CHOP and JNK. JNK has been reported to
be activated by SVA and involved in SVA induced apoptosis of human breast
cancer cells [57]. However, how JNK contributes to SVA induced apoptosis
has not been addressed. Data presented here, for the first time, show that
c-Jun N-terminal kinase (pJNK2/1) mediates SVA induced apoptosis via up-
regulation of CHOP-dependent death receptor DR5 events. JNK has been
reported to activate CHOP via an AP-1 binding site in the CHOP promoter
region in HeLa cells [140]. A JNK/CHOP/DR5 signal transduction pathway
has been reported to be activated and involved in apoptosis induced by several
agents, including methyl-2-cyano-3,12-dioxoolean-1,9-dien-28-oate [88], alpha-
TEA [137] and gamma-tocotrienol [32]. Our data show that SVA induced
apoptosis is also mediated by this JNK/CHOP/DR5 pathway.
Activation of JNK/CHOP/DR5 has been reported to be endoplasmic
reticulum stress dependent [88, 140] and independent [141]. Our data suggest
that SVA induction of JNK/CHOP/DR5 is endoplasmic reticulum stress inde-
pendent because: (i) standard biomarkers of endoplasmic reticulum stress are
not regulated by SVA, such as XBP-1 splicing, ATF-4 and pIeF2 protein ex-
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pression (data not shown), and (ii) the endoplasmic reticulum stress inhibitor
salubrinal did not block SVA induced apoptosis (data not shown).
Another important finding in this paper is that JNK not only con-
tributes to up-regulation of CHOP and DR5, but also contributes to down-
regulation of anti-apoptotic factors c-FLIP and survivin in SVA-induced apop-
tosis. c-FLIP, a protease-deficient caspase-8 homolog, inhibits death receptor
mediated apoptosis via inhibition of caspase-8. Since our data show that SVA
induces activation of caspase-8, the ability of SVA to down-regulate c-FLIP is
proposed to be an important aspect of SVA induced apoptosis. Our data show
that SVA suppression of c-FLIP is JNK dependent. JNK has been reported
to degrade c-FLIP via phosphorylation and activation of the E3 ubiquitin lig-
ase Itch pathway in TNF- and alpha-TEA induced cell death [137, 139]. Our
data showing that siRNA to Itch recovered SVA-induced down-regulation of
c-FLIP, demonstrated for the first time that JNK/Itch pathway is involved in
degradation of c-FLIP, and is critical to SVA-induced apoptosis.
Down-regulation of survivin by SVA has been proposed to play an im-
portant role in SVA induced apoptosis. SVA has been reported to down-
regulate survivin by suppression of Akt in human lung cancer A549 cells [60]
and by suppression of NF-kB in human myeloid KBM-5, squamous cell car-
cinoma SCC4, and human embryonic kidney A293 cells [61]. Our data show
that SVA at higher concentrations (1.25 and 2.5 M in MDA-MB-231 cells,
and 2.5 and 5 M in MCF-7 cells) reduces levels of survivin mRNA, while
SVA at lower concentrations (0.625 M in MDA-MB-231 cells and 1.25 M in
MCF-7 cells) down-regulates levels of protein but not mRNA, suggesting that
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SVA may regulate survivin levels, at least in part at both the transcriptional
and translational levels depending on SVA cellular uptake/retention. Further-
more, data reported here show that survivin is down-regulated by SVA in a
JNK/CHOP-dependent manner. How JNK/CHOP regulates survivin is not
known. Survivin has been shown to be regulated at the post-translation level
in a cell cycle dependent manner with lower expression in the G1 phase and
higher expression in the G2 phase [142]. Endoplasmic reticulum stress has
been shown to down-regulate cyclin D1, leading to a G1 block [143, 144]. Sim-
ilarly, CHOP has been shown to induce cell cycle arrest at G1/S check point
[145]. Our data show that SVA downregulated cyclin D1 (data not shown)
and published data show that SVA induced G1 block [146, 147]. Thus, one
possibility is that JNK/CHOP contributes to the down-regulation of survivin
in SVA induced cell death via CHOP mediated down-regulation of cyclin D1,
leading to G1 block. Since SVA at high doses induces down-regulation of sur-
vivin mRNA, we cannot rule out the possibility that mechanisms other than
G1 block may mediate down-regulation of survivin by SVA.
In agreement with other reports that SVA induced apoptosis can be
inhibited by either exogenous mevalonate or GGPP, but not by exogenous far-
nesyl pyrophosphate (FPP) or by exogenous cholesterol [146], our data demon-
strated that SVA up-regulation of JNK/CHOP/DR5 pro-apoptotic pathway
and down-regulation of anti-apoptotic factors are dependent on lack of meval-
onate and GGPP in human breast cancer cells. It has been shown that inhi-
bition of mevalonate/GGPP reduces Rho signaling which contributes to JNK
activation [148]. However, it is not at all clear how inhibition of Rho sig-
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naling induces activation of JNK. In this regard, it has been reported that
free radicals are generated in SVA induced apoptosis in human breast cancer
cells via suppression of the GGPP/Rho pathway [57, 58]. Other studies have
demonstrated that reactive oxygen species are capable of inducing ER-stress
[149, 150], and to subsequently activate JNK by both ER-stress dependent
[151] and independent mechanisms [152]. However, ROS activation of JNK
via SVA has not been documented.
In agreement with the report from Kotamraju S and co-workers [59] our
data also show that SVA does not induce apoptosis in noncancerous human
epithelia breast cells. Furthermore, our data shows that SVA has no effect
on pro-apoptotic markers CHOP and DR5, as well as anti-apoptotic markers
c-FLIP and Survivin (Figure 7A) in MCF-10A cells, which confirms that SVA
induces apoptosis in breast cancer cells, but not in noncancerous human ep-
ithelia breast cells. However, data show that SVA up-regulates protein levels
of pro-death mediators CHOP and DR5 and down-regulates protein levels of
anti-apoptotic mediators c-FLIP and Survivin in HUVECs (Figure 7A), sug-
gesting that SVA may exert its pro-apoptotic effects on endothelial cells. Thus,
it is of interest to further identify the pro-apoptotic effects of SVA on different
types of non-cancerous cells. Since the growth of HUVEC’s is very impor-
tant for angiogenesis our finding may provide some insight into understanding
SVA’s actions targeting angiogenesis.
Furthermore, to determine the generality of SVA pro-apoptotic events,
studies were conducted using human A2780 ovarian and human LNCaP prostate
cancer cells to evaluate the effects of SVA on the protein expressions of CHOP,
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DR5, c-FLIP and Survivin as well as the involvement of mevalonate pathway.
Data show that SVA increased pro-apoptotic CHOP and DR5 protein lev-
els and decreased anti-apoptotic c-FLIP and Survivin protein levels (Figure
7B). Exogenous mevalonate blocked SVAs ability to up-regulate CHOP and
DR5 and down-regulate c-FLIP and Survivin (Figure 7B). These data demon-
strate that SVA inhibition of the mevalonate pathway, leading to activation
of CHOP/DR5 and suppression of c-FLIP and Survivin, is not breast cancer
specific.
In conclusion, simvastatins dual anticancer actions of activation of pro-
apoptotic and suppression of anti-apoptotic pathways in vitro contribute to
its overall anticancer activity. In this study, we further documented key
events that are involved in the anticancer actions of SVA via inhibition of
Me/GGPP; namely, activation of phosphorylated JNK2/1/CHOP/DR5, and
down-regulation of anti-apoptotic mediators c-FLIP (L) and survivin. Thus,
the findings in this study provide important insights into the apoptotic mech-
anisms of action of SVA and information on biomarkers critical for SVA-
mediated apoptosis which have potential to identify SVA-responsive patients
as well as help with design of combination strategies to enhance the effective-
ness of SVA and reduce toxicity.
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Chapter 3
Targeting ceramide pathways in vitamin E
induced apoptosis in human breast cancer cells
3.1 Abstract
This study examines mechanisms involved in the pro-apoptotic ac-
tion of two vitamin E forms; gamma-tocopherol (γT) and gamma-tocotrienol
(γT3), in human breast cancer cell lines. Previously, we reported that γT3
induces apoptosis via endoplasmic reticulum stress (ERS)-mediated c-Jun N-
terminal kinase (JNK), CCAAT/enhancer binding protein homologous protein
(CHOP), and death receptor-5 (DR5) pro-apoptotic pathway, and γT induces
DR5 dependent apoptosis. Here, we report that γT induces elevated levels
of ERS markers, phospho-JNK (pJNK), CHOP, and DR5 protein expression;
as well as, decreases levels of anti-apoptotic cellular FLICE inhibitory pro-
tein (c-FLIP), B-cell lymphoma 2 (Bcl-2) and Survivin protein expression.
siRNA knockdown of JNK, CHOP, or DR5 show that the ability of γT to
induce apoptosis and suppress anti-apoptotic factors are JNK/CHOP/DR5
pathway dependent. Data also show that both γT and γT3 induce increased
levels of cellular ceramides and dihydroceramides. Inhibition of de novo ce-
ramide synthesis using chemical inhibitors blocked the ability of γT and γT3
to induce apoptosis, to activate JNK/CHOP/DR5 pro-apoptotic pathway, and
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to suppress anti-apoptotic mediators c-FLIP (L), Bcl-2 and Survivin; thereby
demonstrating the involvement of de novo ceramide synthesis in γT- and γT3-
induced apoptosis. Taken together, our data showed that both γT and γT3 in-
duce apoptosis via ceramide mediated ERS, upregulation of JNK/CHOP/DR5
pro-apoptotic signaling and downregulation of anti-apoptotic factors c-FLIP,
Bcl-2 and Survivin.
3.2 Introduction
Breast cancer incidence and death rates remain a major health concern
in the U.S. [1]. In general, systemic treatments, including chemotherapy, hor-
monal, and immunotherapeutic agents, are active at the beginning of therapy
in 90% of primary breast cancers and 50% of metastases [2]. However, treat-
ments are compromised due to initial or acquired drug resistance and toxic side
effects [3, 125]. Therefore, the need for new regimens with low to no toxicity for
breast cancer prevention and therapy remains. Ceramide, a lipid composed
of sphingosine and a fatty acid, is one of the constituents of sphingomyelin
that is a major component of mammalian cell surface and intracellular or-
ganelle membranes. Ceramide is generated in mammals by three independent
processes: de novo synthesis, sphingomyelin hydrolysis and a salvage path-
way [153, 154]. The de novo synthesis of ceramide occurs in the endoplasmic
reticulum (ER) from precursors L-serine and palmitoyl-CoA via several in-
termediates [153, 154]. Ceramide generated in the ER becomes a component
of membrane lipids such as; glycosphingolipids and sphingomyelin. The sph-
ingomyelin hydrolysis pathway converts sphingomyelin to ceramide in cellu-
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lar membranes via sphingomyelinase (SMase) by hydrolysis [153, 154]. In the
salvage pathway, glucosylceramide/lactosylceramide, sphingosine-1-phosphate
or ceramide-1-phosphate is converted to ceramide by cerebrosidase, ceramide
synthases and ceramide-1-phosphate phosphatase, respectively [153, 154]. Ce-
ramide is an important signaling molecule that regulates cellular growth, dif-
ferentiation, and apoptosis [153, 154] and can be regulated by multiple stimuli,
such as oxidative stress, radiation and death receptors [155–157]. Accumula-
tion of ceramide in ER via de novo synthesis has been reported to induce
ERS mediated apoptosis [154]. Whereas, activation of SMase by different
stress signals or apoptotic signals [153–157] causes increase and accumula-
tion of membrane ceramide to form ceramide-enriched lipid raft microdomains
that can serve as platforms for apoptotic signal transmission or amplification
[153, 154, 158]. Vitamin E consists of a group of structurally distinct natu-
rally occurring compounds that are classified as tocopherols (α, β, γ and δ)
and tocotrienols (α, β, γ and δ), and synthetic forms such as all-racemic-α-
tocopherol (all-rac-αT; also referred to as dl-α-tocopherol); as well as, vitamin
E analogs such as vitamin E sucinate (VES) and RRR-α-tocopherol ether-
linked acetic acid analogue (α-TEA) (reviewed in [6]). A subset of vitamin
E compounds have been shown to be effective anticancer agents in vitro and
in vivo, including γ- and δ-forms of tocopherol and tocotrienol (reviewed in
[24, 159]). Accumulating evidence supports that γT, the most abundant form
of vitamin E in the American diet, and γT3 obtained from palm oil, wheat
germ, rice bran and barley, possess anticancer properties [24, 159]. Both γT
and γT3 have been shown to inhibit tumor growth in a number of animal mod-
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els and these anticancer effects are attributed to both induction of apoptosis
and cell cycle arrest [24, 27, 32, 159]. γT and γT3 induced apoptosis has been
reported in colon, prostate and breast cancer cell lines and involves activation
of caspases -3, -7, -8 and /or -9 and release of cytochrome c [24, 27, 32, 159].
The extrinsic death receptor DR5 and alteration of sphingolipid pathways
have been demonstrated to be necessary for γT- and γT3-induced apopto-
sis [27, 28, 32, 160]. Previously, we reported that γT3 induce DR5 dependent
apoptosis via ERS mediated JNK and CHOP [32]. Here, for the first time,
we demonstrate that γT also induces JNK/CHOP/DR5 dependent apopto-
sis and that it down-regulates key pro-survival/anti-apoptotic factors c-FLIP,
Survivin, and Bcl-2. Furthermore, data show that de novo ceramide synthesis
is activated and involved in both γT- and γT3-induced apoptotic events.
3.3 Materials and Methods
3.3.1 Chemicals
γT and γT3 were gift from TAMA Biochemical Company (LTD, Tokyo,
Japan) and Malaysian Palm Oil Board (Kuala Lumpur, Malaysia), respec-
tively. Myriocin (My), an inhibitor of serine palmitoyltransferase that is the
first limited enzyme in de novo ceramide synthesis pathway, was obtained from
BioMol (Plymouth Meeting, PA). C8-cyclopropenylceramide (C8CPPC), an
inhibitor of the dihydroceramide desaturase enzyme, involved in the final step




MCF-7 and MDA-MB-435 human breast cancer cell lines were cultured
as previously described [14]. SUM159 human breast cancer cells (Asterand,
Inc. Detroit, MI) were cultured in Hams F12 medium (Invitrogen, Carlsbad,
CA) with 5% fetal bovine serum (FBS), 5 µg/ml insulin, 1µg/ml hydrocor-
tisone (Sigma-Aldrich, St Louis, MO), and 10 mM HEPES buffer. Acquired
adriamycin/doxorubicin (AD) resistant MCF-7 (MCF-7/ADR; obtained from
Dr. Kapil Mehta, M.D. Anderson Cancer Centre, Houston TX) and Acquired
tamoxifen (Tam) resistant MCF-7 (MCF-7/TamR; obtained from Dr. Linda
deGraffenried, University of Texas at Austin, Austin, TX) human breast can-
cer cell lines were derived by selection from parental cells cultured in the pres-
ence of doxorubicin or tamoxifen, respectively and cultured in the conditions
described previously [132, 133]. For experiments, FBS was reduced to 2%. γT
and γT3 were dissolved in 1:4 DMSO/ethanol at 40 mM as stock solution.
Equivalent levels of 1:4 DMSO/ethanol was used as vehicle control (VEH).
3.3.3 Quantification of apoptosis
Apoptosis was quantified by Annexin V-FITC/PI assays following the
manufacturers instructions (Invitrogen, Carlsbad, CA) and published proce-
dure [32]. Annexin V/FITC was a gift from (Dr. Shawn Bratton, University
of Texas at Austin).
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3.3.4 Western blot analyses
Western blot analyses were conducted as described previously [32]. Pri-
mary antibodies to the following proteins were used in this study; PARP,
pJNK, total JNK, GRP-78, CHOP, cFLIP, Bcl-2 and Survivin (Santa Cruz
Biotechnology, Santa Cruz, CA), DR5 (Cell Signaling) and glyceraldehyde-3-
phosphate dehydrogenase (GAPDH, made in house). Secondary antibodies
used included: horseradish peroxidase conjugated goat-anti-rabbit and rabbit-
anti-mouse (Jackson Immunoresearch, Rockford, IL); and bovine-anti-goat
(Santa Cruz Biotechnology).
3.3.5 Small interfering RNA (siRNA) transfections
A scrambled RNA duplex that does not target any known genes was
used as the nonspecific negative control for RNAi (referred to as control
siRNA). Transfection of siRNAs to JNK1/2, CHOP, DR5 or control (Ambion,
Austin, TX) was performed as described previously [27, 32].
3.3.6 Lipid extraction and measurement of sphingolipids using LC-
MS/MS
Lipid was extracted according to the method published before [133].
Briefly, cell pellets were resuspended in 500 µL of methanol, 250 µL of chloro-
form and 50 µL of water after the addition of 20 µL of internal standard mix-
ture (Avanti Polar Lipids, Alabaster, AL). The suspension was tip sonicated
for 20 sec and then incubated overnight at 48 oC. 100 µL of the suspension
was taken to determine total choline-containing phospholipids as previously
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described [28], and the rest was added with 75 µL of 1M potassium hydroxide
in methanol and sonicated for 30 min. Samples were incubated at 37 oC for 2
h and evaporated under a stream of nitrogen. Immediately prior to the analy-
sis, samples were resuspended in methanol, sonicated and briefly centrifuged.
The LC-MS/MS analyses of sphingolipids were performed using Agilent 6460
triple quadrupole mass spectrometer coupled with the Agilent 1200 Rapid Res-
olution HPLC (Agilent Technologies, Santa Clara, CA) in positive mode by
multiple reaction monitoring technique. The HPLC mobile phases consisted
of methanol-H2O-formic acid (74:25:1, v/v/v; RA) and methanol-formic acid
(99:1, v/v; RB); both RA and RB contain 5 mM ammonium formate [161].
For measurement of ceramide and sphingoid bases, Agilent column XDB-C18,
particle size 1.8 µm, 4.6 x 50 mm was used with isocratic run (100% RB,
for ceramide) or gradient (0-1min, 20% B, 10-13min, 100%B and 15-20min at
20%B for sphingoid bases). The source parameters were as follows: gas tem-
perature, 350oC; gas flow rate, 10 L/min; nebulizer pressure, 50 psi; capillary
voltage, 3500 V; The fragmentor voltage was 100 V and collision energy was
20 V.
3.3.7 Statistical Analysis
The students t-test was used to determine statistical differences be-
tween treatment and control values. Differences were considered statistical
significant at p < 0.05.
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3.4 Results
3.4.1 pJNK2/1 and CHOP is upregulated in γT induced apoptosis
Since previous data showed that γT induces apoptosis via upregulation
of DR5 protein expression [27] and γT3 induced DR5 dependent apoptosis
via ERS mediated JNK/CHOP [32], it was of interest to see if events similar
to those reported for γT3 were activated in γT induced apoptosis. Hence,
we analyzed the impact of γT on the induction of pJNK and ERS inducible
protein CHOP that plays a critical role in apoptosis. Treatment of MCF-7,
MDA-MB-435 and SUM 159 breast cancer cells with increasing doses of γT
for 3 days induced increased levels of pJNK 2/1, CHOP and DR5 long/short
(L/S) in a dose response manner (Figure 3.1A). Similar results were observed
in MCF-7/TamR and MCF-7/ADR cell lines (Figure 3.1B).
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Figure 3.1: pJNK and CHOP is upregulated in γT induced apopto-
sis.Cells were treated with increasing doses of γT for 3 days followed
by western blot analyses to determine protein levels (A and B). Data
in A and B are representative of two or more independent experi-
ments.
3.4.2 γT induces endoplasmic reticulum stress (ERS)and decreased
anti-apoptotic mediators c-FLIP, Bcl-2 and Survivin protein
levels
Proof that γT was inducing ERS was generated by assessing protein
expression levels of known ERS markers. Treatment of cells with γT for 3 days
induced increased levels of ERS markers GRP78, ATF4 and peIF2α in a dose
dependent manner (Figure 3.3A), suggesting that γT induces ERS.Treatment
of cells with increasing doses of γT for 3 days also decreased anti-apoptotic
mediators c-FLIP (L), Bcl-2 and Survivin protein levels (Figure 3.3 B). These
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data show that γT induced apoptosis is accompanied by suppression of anti-
apoptotic mediators.
Figure 3.2: γT induced ERS and reduced anti-apoptotic factors
c-FLIP, Bcl-2 and Survivin.The protein levels of ERS-related factors
GRP78, ATF-4 and peIF-2α as well as anti-apoptotic factors c-Flip,
Bcl-2 and Survivin were determined by western blot analyses. Data
are representative of two or more independent experiments.
3.4.3 γT upregulation of pro-apoptotic and anti-apoptotic factors
as well as apoptosis is JNK dependent
Since γT3 induced apoptosis was shown to be mediated by JNK de-
pendent activation of CHOP and DR5 [32], it was important to determine if
γT induced apoptosis involved a similar pro-apoptotic axis. siRNA to JNK,
CHOP and DR5 significantly reduced γT induced apoptosis as detected by
annexin V (Figure 3.3A) and PARP cleavage (Figure 3.3B), and markedly
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reduced pJNK/CHOP/DR5 protein levels (Figure 3.3B), showing that JNK
is an upstream mediator of CHOP and DR5 in γT induced apoptosis. These
siRNA knockdown outcomes also suggest a cyclic loop rather than a sequen-
tial series of events. Furthermore, siRNA to JNK, CHOP or DR5 reduced the
ability of γT to downregulate anti-apoptotic mediators cFLIP (L), Bcl-2, and
Survivin (Figure 3.3B). Data suggest that these anti-apoptotic mediators are
downregulated by JNK/CHOP/DR5 during apoptosis triggered by γT.
3.4.4 De novo ceramide synthesis pathway is involved in both γT
and γT3 induced apoptotic events
Previous data show that the de novo ceramide synthesis pathway is
involved in both γT and γT3 induction of apoptosis of human prostate cancer
cells [28, 160]. Here, we determined if the de novo ceramide synthesis path-
way is involved in γT and γT3 induced apoptotic events in human breast
cancer cells. Treatments of MCF-7 cells with γT and γT3 for 3 days induce
apoptosis in a dose-dependent manner (Figure 3.4A). Furthermore, γT3 was
observed to be more effective than γT. Pre-treatment of MCF-7 cells with
either of two de novo ceramide synthesis inhibitors: Myriocin (My) or C8-
cyclopropenylceramide (C8CPPC) for 2 hours followed by treatment with γT
or γT3 for 3 days significantly reduced the ability of γT and γT3 to induce
apoptosis as determined by annexin V analyses (Figure 3.4B) and cleavage
of caspases-8 and -9; as well as, PARP (Figure 3.4C). Furthermore, the two
inhibitors reduced the ability of γT and γT3 to up-regulate pJNK, CHOP and
DR5 (L/S) protein levels, and to downregulate c-FLIP (L), Bcl-2 and Survivin
63
Figure 3.3: γT induced apoptosis, upregulation of pro-apoptotic
mediators as well as downregulation of anti-apoptotic mediators are
JNK, CHOP and DR5 dependent. Cells transfected with siRNA
to JNK2, CHOP, DR5 or control were treated with γT for 3 days
followed by Annexin V/FACS analyses and western blot analyses to
determine apoptosis (A) and protein levels (B), respectively. Data
in B are representative of two or more independent experiments.
Data in A are depicted as the mean ± S.D. of three independent
experiments. *significantly reduced in comparison to control siRNA,
P < 0.05.
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(Figure 3.4C). These data suggest that apoptotic events induced by γT and
γT3 involve de novo ceramide synthesis pathway.
3.4.5 γT and γT3 induce increased levels of cellular ceramides and
dihydroceramides
To further investigate the involvement of ceramides in γT- and γT3-
induced apoptosis, we determined the effects of γT and γT3 on intracellular
ceramide levels. Results show that treatment with either γT or γT3 for 2 or
3 days induced increased levels of 16-ceramide (16 Cer), 24-ceramide 24:1 [24
Cer (24:1)] and total ceramide (total Cer) (Figure 3.4D) and increased the
levels of 16-dihydroceramide (DH-16 Cer), 24-dihydroceramide 24:1 [DH-24
Cer (24:1)] and total dihydroceramide (DH-total Cer) (Figure 3.4E) compared
with VEH control. γT or γT3 treatment also induces increased levels of C18-,
C20-, C22-, C24-(24:0) and C26-ceramide; as well as, dihydroceramide and
dihydrosphingosine (data not shown). Taken together, these data further sup-
port a role for de novo ceramide synthesis in γT- and γT3-induced apoptosis.
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Figure 3.4: De novo ceramide synthesis pathway is involved in γT-
and γT3-mediated apoptotic events.Cells were treated with increas-
ing doses of γT and γT3 for 3 days followed by Annexin V/FACS
analyses to determine apoptosis (A). Cells were pre-treated sepa-
rately with two de novo ceramide synthesis inhibitors, Myriocin (My)
or C8-Cyclopropenylceramide (C8CPPC) for 2 hours, followed by γT
and γT3 for 3 days. Apoptosis was evaluated by Annexin V/FACS
analyses (B) and protein levels were determined by western blot anal-
yses (C). The levels of cellular ceramides (D) and dihydroceramides
(E) were determined using methods described in the Material and
Methods section. Data in A, B, D and E are depicted as the mean ±
S.D. of three independent experiments. Data in C are representative
of two or more independent experiments. *significantly increased in
comparison to VEH control, P < 0.05. **significantly reduced in
comparison to γT or γT3 treatment alone, P < 0.05.
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3.4.6 Sphingomyelin hydrolysis pathway is involved in γT and γT3
induced apoptotic events
Treatment of MCF-7 breast cancer cells with 2.5 µM ASM inhibitor,
Despiramine (Des), an inhibitor of acid spingomyelinase for 2 hours, followed
by treatment with 40 µM γT or 10 µM γT3 for 3 days reduced the ability of γT
or γT3 to induce MCF-7 cells to undergo apoptosis as determined by Annexin
V and cleavage of PARP (Fig 3.5 A & B), activation of caspases 8 and 9 (Fig
3.5 B), increased levels of pJNK2/1, CHOP and DR5 (L/S), and decreased
anti-apoptotic mediators c-FLIP, Bcl-2, and Survivin (Fig 3.5 C). These data
show that ceramide synthesis is critical to the apoptotic inducing properties
of γT and γT3, and that inhibition of ceramide generation via hydrolysis by
ASM inhibits the ability of γT or γT3 to induce apoptotic cell death.
Based on data presented and published [27, 28, 159, 160, 162], we pro-
pose the following signaling events in γT and γT3 induced apoptosis of human
breast cancer cells (Figure 3.6). Treatment of human breast cancer cells with
γT or γT3 activates both the de novo ceramide synthesis pathway and gener-
ation of ceramide by ASM hydrolysis of sphingomyelin, resulting in enhanced
levels of ceramide in cell surface membranes, and induction of endoplasmic
reticulum stress. Endoplasmic stress mediators JNK/CHOP/DR5 inhibit anti-
apoptotic mediators c-FLIP, Bcl-2, and survivin, and activate DR5 creating a
DR5/JNK/CHOP/DR5 amplification loop involving caspase 8 and 9 mediated
apoptosis.
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Figure 3.5: Sphingomyelin hydrolysis pathway is involved in γT-
and γT3-mediated apoptotic events. MCF-7 cells were pre-treated
with Despiramine (Des), an inhibitor of acid spingomyelinase for 2
hours, followed by treatment with 40 µM γT or 10 µM γT3 for 3days.
Apoptosis was evaluated by Annexin V/FACS analyses (A). Cleaved
PARP (c-PARP), caspase-8, caspase-9, p-JNK (2/1), CHOP, DR5,
GRP78, c-FLIP (L), Bcl-2 and Survivin protein levels were deter-
mined by western blot analyses (B and C). B and C data are represen-
tative of two or more independent experiments. A data are presented
as the mean S.D. of three independent experiments. *significantly
reduced in comparison to γT and γT3 treatments, P < 0.05.
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Figure 3.6: Proposed signaling events for γT and γT3 induced
apoptosis in human breast cancer cells.Based on published data and
data present we proposed the following signaling events that may
be involved in γT and γT3 induced apoptosis of human breast can-
cer cells; (i) γT or γT3 induce elevated levels of cellular ceramide
via de novo ceramide synthesis pathway and sphingomyelin hydrol-
ysis pathway, leading to induction of ERS, (ii) γT or γT3 upreg-
ulates JNK/CHOP/DR5 positive loop via ERS, (iii) Upregulation
of JNK/CHOP/DR5 positive loop triggers caspae-8 and caspase-9
(including mitochondria) dependent apoptotic cascade, and down-
regulates anti-apoptotic factors c-FLIP, Bcl-2 and Survivin, and (iv)
Downregulation of the anti-apoptotic factors promotes γT- or γT3-




Although γT and γT3 possess anticancer actions, a complete under-
standing of the complex mechanisms involved remains unclear. Here, for the
first time, studies demonstrate that γT, in a similar manner to γT3, induces
apoptosis in human breast cancer cells via activation of JNK/CHOP/DR5
mediated pro-apoptotic events and suppresses anti-apoptotic factors, c-FLIP,
Bcl-2 and Survivin, which are dependent; at least in part, on elevated lev-
els of ceramide generated by the de novo ceramide synthesis pathway. Novel
findings include: (i) Like γT3, γT induces apoptosis of human breast can-
cer cells via upregulation of pJNK, CHOP and DR5 protein expression, (ii)
Although γT has been reported previously to decrease the expression of the
cellular pro-survival protein Survivin [27], these studies show that apoptosis
induced by both γT and γT3 involves simultaneous downregulation of three
key anti-apoptotic factors c-FLIP, Bcl-2, and Survivin, (iii) Both γT and γT3
induce increased levels of total cellular ceramides and dihydroceramides, and
(iv) De novo ceramide synthesis and sphingomyelin hydrolysis is involved in
both γT and γT3 apoptotic events. Taken together, these studies provide
a better understanding of signaling pathway elements that can be success-
fully targeted to achieve improved clinical benefit in cancer prevention and
therapy. Activation of DR5, leading to cell death, has been observed to specif-
ically occur in cancerous cell types while sparing normal cells [163]. This
has led to the development and use of DR4/DR5 targeted antibody thera-
pies [163]. A number of anticancer agents have been identified as mediating
their anticancer actions at least in part via upregulation of DR5 including
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several vitamin E compounds; namely, VES [164], α-TEA [165], γT [27] and
γT3 [32]. DR5 can be upregulated by multiple factors such as NF-κB, p53,
JNK and CHOP [86, 87, 166, 167]. Previous data show that ERS contributes
to both α-TEA- and γT3-induced DR5 dependent apoptosis via activation
of JNK/CHOP [32, 137]. Here, we reported that γT induced DR5 mediated
apoptosis also requires JNK and CHOP. Since data also show that γT induces
ERS we hypothesized that, like γT3, γT upregulation of JNK/CHOP/DR5 is
ERS dependent. c-FLIP, Bcl-2 and Survivin play important protective roles in
caspase-8 and mitochondria mediated apoptotic cascades. It is not surprising
that c-FLIP and Bcl-2 are downregulated by γT via JNK/CHOP/DR5 path-
way, since we have reported that α-TEA downregulated c-FLIP and Bcl-2 via
the same pathway [137]. However, the finding that Survivin downregulation
in γT mediated apoptosis is also regulated by JNK/CHOP/DR5 pathway is
totally unexpected. How JNK/CHOP/DR5 pathway downregulates Survivin
is not known. CyclinD1 has been reported to target Survivin by degradation
in a G1 block dependent manner [143] and cyclin D1 in turn has been shown
to be down-regulated at protein levels by ERS [168]. Thus, it is possible that
ERS activation contributes to Survivin degradation in γT mediated apopto-
sis. This hypothesis is supported by data showing that (i) both γT and γT3
induce ERS (Figure 4) [32] and G1 cell cycle arrest [12]; as well as, down-
regulate cyclinD1 (data not shown) and (ii) γT downregulation of Survivin
occurs at the protein level, but not at the mRNA level (data not shown). In
agreement with previous reports in prostate cancer cells [28, 160], data pre-
sented here show that the de novo ceramide synthesis pathway is involved in
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γT- and γT3-induced apoptosis in breast cancer cells. Importantly, our data
showing that inhibition of de novo ceramide synthesis using inhibitors; Myri-
ocin and C8CPPC that specifically inhibit both the first and final enzymes
in the de novo pathway, respectively, blocked γT and γT3 induced apoptotic
events suggest that ceramide generated by the de novo synthesis pathway is
involved in γT and γT3 induced apoptosis in human breast cancer cells. Data
showing that γT and γT3 induce increased levels of total ceramide, further
support involvement of ceramide generation in γT and γT3 induced apop-
tosis. Also, data documenting increases in the levels of dihydroceramides,
an important intermediate in the de novo pathway, adds further support for
the involvement of the de novo ceramide pathway in γT and γT3 mediated ef-
fects. It is interesting to note that unlike previous studies showing that γT and
γT3 induce accumulation of dihydroceramide and dihydrosphingosine without
affecting ceramide during the early-stage of γT or γT3 treatment in prostate
cancer cells [28, 160], here we observe that these vitamin E forms increase both
cellular ceramide and dihydroceramide in breast cancer cells. These cell type
dependent effects may be due to different activities of key enzymes involved
in ceramide metabolism, which warrants further investigation. Sphingomyelin
hydrolysis has been shown to be activated in response to stress stimuli gen-
erated by death receptors, chemotherapeutic agents, infections, gamma and
UV radiation [154]. Previously, sphingomyelin hydrolysis was shown to be
involved in apoptosis induced by a modified form of vitamin E, γ-TEA [158].
Interestingly, data reported here show that sphingomyelin hydrolysis is also
involved in apoptotic events induced by γT and γT3. Data showing that both
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the de novo ceramide synthesis pathway and sphingomyelin hydrolysis simul-
taneously contribute to γT and γT3 induced ER-stress and apoptosis are in
agreement with the work done by Sauane et al 2010 in prostate cancer cells
treated with novel therapeutic agent recombinant melanoma associated gene-
7/interleukin 24 (mda7/IL24). However, the mechanisms whereby γT and γT3
regulate both de novo ceramide synthesis and sphingomyelin hydrolysis are not
understood. The regulation of ceramide synthesis pathways is complicated. It
is not clear if both agents individually activate distinct upstream mediators
or common mediators to induce both sphingomyelin hydrolysis and de novo
synthesis simultaneously or the two pathways are activated in a specific se-
quence. Further work will have to be carried out to identify the sequence of
events. Based on published data and data present here a schematic diagram of
proposed signaling events in γT and γT3 induced apoptosis of human breast
cancer cells are depicted in Fig 3.6. In conclusion, these studies show that
the naturally occurring forms of vitamin E, γT and γT3, induce apoptosis
through activation of pro-apoptotic JNK/CHOP/DR5 mediated events and
down-regulation of anti-apoptotic factors c-FLIP, Bcl-2 and Survivin via in-
creased levels of ceramide generated by the de novo ceramide synthesis and
sphingomyelin hydrolysis pathway. These studies provide insights for better
understanding of the anticancer actions of vitamin E and increased knowledge
into how targeting ERS can mediate pro-apoptotic pathways which may be
beneficial in prevention and therapy of human breast cancer.
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Chapter 4
Eliminating tumor initiating and bulk drug
resistant breast cancer cells with combination
of simvastatin and gamma-tocotrienol
4.1 Abstract
This study examines the anticancer action of simvastatin (SVA) and
gamma-tocotrienol (γT3) alone and in combination on eliminating tumor ini-
tiating cells (TICs) and non-TICs in drug resistant human breast cancer cell
lines; namely, acquired tamoxifen (Tam) resistant MCF-7 (MCF-7/TamR) and
acquired adriamycin/doxorubicin (AD) resistant MCF-7 cells (MCF-7/ADR).
Here, we report that both drug resistant cell lines contain higher percentages
of aldehyde dehydrogenase activity positive (ALDH+) and CD44+/CD24-
populations in comparison with the parental cell lines. ALDH+ populations
from both cell lines exhibit the capacity to self-renew and ability to form
colonies, two characteristics of TICs, as determined by mammosphere and
colony formation assays, respectively, indicating that TICs are enriched in
ALDH+ populations. Both drug resistant cell lines expressed higher levels
of signal transducer and activator of transcription 3 (Stat-3) phosphorylated
at tyrosine-705 (pStat-3, Tyr-705), c-Myc, CyclinD1, Bcl-xL and Survivin in
comparison with their parental cell lines and pStat-3, c-Myc, Cyclin D1, Bcl-
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xL and Survivin are highly expressed in ALDH+ in comparison with either
ALDH- or unsorted cells. Knockdown of Stat-3 using a chemical inhibitor of
Stat-3, reduced ALDH+ and CD44+/CD24- populations, inhibited mammo-
sphere formation, and decreased pStat-3, c-Myc, CyclinD1, Bcl-xL and Sur-
vivin protein expression, indicating that Stat-3 is critical for maintaining TICs
in these cell lines. SVA and γT3 alone and in combination reduced ALDH+
and CD44+/CD24- populations, inhibited mammosphere formation, and de-
creased pStat-3, c-Myc, CyclinD1, Bcl-xL and Survivin protein expression in
both unsorted and ALDH+ population. Furthermore, SVA and γT3 either
singly or in combination induced apoptosis which is associated with activation
of JNK/CHOP/DR5 pro-apoptotic events that have been reported previously
to be involved in both SVA and γT3 induced apoptosis in parental MCF-7
cells. Taken together, these in vitro data demonstrate that drug resistant hu-
man breast cancer cell lines contain higher levels of a TIC enriched population
which is regulated in part via highly expressed pStat-3, and that the combi-
nation of SVA plus γT3 has the ability to target both the enriched TIC and
bulk cancer cell populations .
4.2 Introduction
Breast cancer is the second leading cause of cancer death in women in
the U.S [1]. Despite great advances in therapeutic strategies devised specifi-
cally to target various sub-types of breast cancer, acquisition of drug resistance
and treatment associated side effects compromise effectiveness. Hence, a bet-
ter understanding of the molecular changes observed in drug resistance and
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strategies to overcome it with low/nontoxic interventions is required to improve
the overall disease-free survival rates. Accumulating data support the concept
that breast tumors originate from breast cancer stem and/or progenitor cells,
which are referred to as either tumor initiating cells (TICs) or cancer stem cells
(CSCs) [169]. TICs represent a small population of cancer cells that exhibit
self-renewal and differentiation characteristics similar to normal stem cells but
differ in that their self-renewal pathways are deregulated [107, 169]. Based
on the TIC concept, TICs are responsible for tumor formation, progression,
metastasis, and recurrence; as well as, drug resistance [107, 170]. The con-
cept of TICs has profound implications for early detection, prevention, and
treatment of cancer [107, 170, 171]. Thus, targeting TICs provides a promising
approach for cancer prevention and treatment, especially for drug resistant
breast cancer.
Signal transducer and activator of transcription 3 (Stat-3) is activated
in response to cytokine and growth factor signaling. Activation of stat-3 by
Janus Associated Kinase (JAK) or growth factor receptor-associated tyrosine
kinase (Src) involves phosphorylation of 705 tyrosine residue at C-terminal
domain. Phosphorylated Stat-3 forms homo- or hetero-dimer that translo-
cate to the nucleus and binds to DNA binding domains of the regulated genes
[121, 172]. Active Stat-3 has been observed to be highly expressed in mul-
tiple tumors including breast cancer. Activated Stat-3 can transcriptionally
regulate pro-proliferation or TIC-factors such as c-Myc, CyclinD1, Bcl-xL and
Survivin in addition to regulating genes associated with invasion and angiogen-
esis. Although breast cancer cell lines and tumor tissues have been identified
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to express high levels of active Stat-3, the role of Stat-3 in development of
drug resistance and associated TIC in breast cancer has not been identified
[121, 172].
Presently, treatments including anti-hormones such as tamoxifen (Tam),
chemotherapeutic such as adriamycin/doxorubicin (ADR/DOX), and biolog-
ical agents, are used in both adjuvant and neo-adjuvant settings. They have
been observed to be effective in 90% of primary breast cancers and 50% of
metastases at the start of the therapeutic period. However, eventually resis-
tance to therapy and toxic side effects develops [2, 173, 174]. At this stage
the tumors may also present with cross-resistance to other therapeutic agents.
A number of molecular changes have been identified to be associated with
progression of therapeutic resistance and recurrent disease [2, 173, 175], in-
cluding increased cross-talk between various receptor tyrosine kinase signaling
pathways, alterations of apoptotic mediators and DNA repair mechanisms,
decreased activation of drug; as well as, increased drug efflux from the cells
[2, 173, 175]. However, the complete accounting of mechanisms involved has
not been achieved. Simvastatin (SVA) is one of the family of statin drugs that
are the most widely prescribed drugs used for the reduction of cholesterol lev-
els via inhibition of 3-hydroxy-3-methyl-glutaryl-CoA reductase (HMG-CoA)
reductase, the enzyme that catalyzes the rate-limiting step in mevalonate syn-
thesis [130]. A growing body of information over the past decade suggests
that statins possess potential for use in cancer management [50–56, 130, 131].
Numerous in vitro and preclinical studies have shown that various statins, par-
ticularly lipophilic statins such as SVA have antiproliferative, antiangiogenic,
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antimetastasis and pro-apoptotic properties in many types of cancer cells in-
cluding breast cancer [50–56, 130, 131]. Moreover, Gauthaman et al., provided
evidence for anti-TIC effects of SVA in karyotypically abnormal mouse embry-
onic stem cells [176]. Vitamin E consists of a group of structurally distinct
naturally occurring compounds that are classified as tocopherols (α, β, γ and
δ) and tocotrienols (α, β, γ and δ). The general term vitamin E is also used for
synthetic vitamin E (all-rac-α-tocopherol); as well as, vitamin E analogs such
as vitamin E succinate (VES) and RRR-α-tocopherol ether-linked acetic acid
analogue (α-TEA). Some, but not all vitamin E compounds, display anticancer
properties in vitro and in vivo [24]. Of the naturally occurring forms, accu-
mulating evidence supports that γT3 possesses potent anticancer properties,
including inhibition of tumor growth in vivo and inhibition of cell proliferation,
metastasis and angiogenesis; as well as, induction of apoptosis in vitro. Re-
cently, γT3 has been reported to have the ability to eliminate TICs in prostate
cancer [124]. The combination of SVA plus γT3 has been shown to exhibit
better anticancer actions than either agent by itself in mammary cancer [177].
Here, we investigated the anticancer effects of SVA and γT3 singly; as well as,
in combination in targeting both TIC and bulk tumor cells from drug resis-
tant human breast cancer cell lines; namely, MCF-7/TamR and MCF-7/ADR.
We report that both SVA and γT3 alone and in combination target TIC via
elimination of TIC enriched population and bulk tumor cells via induction
of apoptosis, suggesting that the combination of SVA + γT3 is a potential
regimen for prevention and treatment of drug resistant breast cancer.
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4.3 Materials and Methods
4.3.1 Chemicals
Simvastatin sodium salt (SVA), an active form of simvastatin in vitro,
was obtained from Calbiochem (San Diego, CA). JSI-124 (Cucurbitacin I),
an inhibitor of phosphorylation of Stat3 at Tyr-705 [178], was purchased from
Calbiochem (Cambridge, MA). γT3 was a gift from Malaysian Palm Oil Board
(Kuala Lumpur, Malaysia).
4.3.2 Cell Culture
MCF-7/ADR and MCF-7/TamR cells which were derived by selection
of parental cells in the presence of doxorubicin and tamoxifen respectively,
were obtained from Dr. Kapil Mehta, (M.D Anderson Cancer Center, Houston
TX) and Dr. Linda deGraffenried (University of Texas at Austin, Austin, TX),
respectively. Cells were maintained and cultured as published before [133, 179].
For experiments, FBS was reduced to 2%. γT3 was dissolved in 1:4 (vol/vol)
DMSO/ethanol at 40 mM as stock solution. SVA was dissolved in ethanol.
Equivalent levels of 1:4 (vol/vol) DMSO/ethanol was used as vehicle control
(VEH).
4.3.3 Quantification of apoptosis
Apoptosis was quantified by Annexin V-FITC/PI assays following the
manufacturers instructions (Invitrogen, Carlsbad, CA) and previously pub-
lished procedures from our lab [32]. Annexin V/FITC was a gift from Dr.
Shawn Bratton, (M. D. Anderson Cancer Center, Smithville, TX).
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4.3.4 Western blot analyses
Western blot analyses were conducted as described previously [32]. Pri-
mary antibodies to the following proteins were used in this study; PARP, GRP-
78, pJNK, CHOP, c-Myc, CyclinD1, Bcl-xL and Survivin (Santa Cruz Biotech-
nology, Santa Cruz, CA), DR5, Caspase-8, Caspase-9, pStat-3 and Stat-3 (Cell
Signaling), and glyceraldehyde-3-phosphate dehydrogenase (GAPDH, made
in house). Secondary antibodies used included: horseradish peroxidase conju-
gated goat-anti-rabbit and rabbit-anti-mouse (Jackson Immunoresearch, Rock-
ford, IL); and bovine-anti-goat (Santa Cruz Biotechnology).
4.3.5 Analysis of aldehyde dehydrogenase activity
ALDH activity was determined using an Aldefluor assay kit (StemCell
Technologies, Inc, Vancouver, BC, Canada) as per the manufacturers instruc-
tions. Aldefluor fluorescence was detected using a FL1 detector in a LSRII
flow cytometer and analyzed using BD FACSDiVa software.
4.3.6 Mammosphere formation and limiting dilution assays
ALDH+, ALDH- and unsorted MCF-7/TamR and MCF-7/ADR cells
were assessed for ability to form mammospheres using established mammo-
sphere formation conditions [132]. Cells were cultured in DMEM/F12 phe-
nol red free (MCF-7/TamR) and phenol red (MCF-7/ADR) medium supple-
mented with fibroblast growth factor (10 ng/mL) and epidermal growth factor
(10 ng/mL; Preprotech, Rocky Hill, NJ); insulin (50 µg/mL; Sigma Chemi-
cal Co); and B27 (100 units/mL), N2 supplements (100 units/mL), penicillin
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(100 units/mL), and streptomycin (100 g/mL) (Invitrogen). Serial dilutions
of cells were plated in 24 well ultra low attachment plates and cultured for 7
days [132]. Mammospheres were characterized as spherical organoids of more
than 50 cells. The number of mammospheres was scored using microscope
with regular light and 100 x magnification.
4.3.7 Analysis of the cell surface expression of CD44 and CD24 by
immunostaining and flow cytometry
Cells were washed with 0.5% BSA in PBS and incubated with IgG2b
species specific antibody for 15 minutes at 4oC. CD44 and CD24 (BD Pharmin-
gen, San Diego, CA) fluorochrome-conjugated antibodies were added as per
the manufacturers instructions and incubated for 30 minutes at 4oC. Cells
were washed with 0.5%BSA in PBS and 7-AAD was added to samples prior
to analysis to exclude non-viable cells. CD44-APC was detected using FL5
and CD24-PE was detected using FL2 filters in a LSRII flow cytometer and
analyzed using BD FACSDiVa software.
4.3.8 Colony formation assay
400, 200 and 100 cells/12 wells were cultured on 12 well tissue culture
plastic plates for 14 days followed by fixing the cells with methanol and staining
with 2% (w/v) crystal violet in H2O. Colonies containing more than 50 cells
were scored [116, 180, 181].
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4.3.9 Statistical Analysis
The data were analyzed using two-tailed student t-test for comparison
between two treatments to determine statistical differences. Differences were
considered statistical significant at p < 0.05.
4.4 Results
4.4.1 Drug resistant MCF-7/TamR and MCF-7/ADR cell lines
contain higher levels of ALDH+ and CD44+/CD24- TIC
cell populations in comparison to the drug sensitive (MCF-
7/TamS or MCF-7) parental cell lines.
Cell sorting analyses based on ALDH+ and CD44+/CD24- TIC mark-
ers show that MCF-7/TamR and MCF-7/ADR cell lines have 6.2 1.11% and
6.8 0.56% ALDH+ cells versus 0.3 0.02% and 0.1 0.05% in their MCF-
7/TamS and MCF-7 parental counterparts (Fig 4.1A), and the MCF-7/TamR
and MCF-7/ADR cells have 60.4 2.71% and 30.4 1.53% CD44+/CD24- cells
versus 1.3 0.56% and 0.8 0.26% in their parental cell counterparts (Fig 4.1B).
Furthermore, MCF-7/TamR and MCF-7/ADR cells have 5.5 0.21% and 1.25
0.07% ALDH+/CD44+/CD24- cells versus 0.2 0.1% and 0% in MCF-7/TamS
and MCF-7 cells respectively (Fig 4.1C).
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Figure 4.1: The percentages of ALDH+, CD44+/CD24- and
ALDH+/CD44+/CD24- were determined using ALDH activity as-
say (A), CD44/CD24 immunostaining assay (B) and both assays (C),
respectively. Data are representative images of three independent ex-
periments.
4.4.2 ALDH+ populations are enriched in tumor initiating cells.
To confirm the tumor initiating properties of ALDH+ populations,
MCF-7/TamR and MCF-7/ADR cells were sorted into ALDH+ and ALDH-




Sorted ALDH+ cells 6.03 ± 0.47* 6.30 ± 0.78*
Sorted ALDH− cells 0.87 ± 0.38 0.07 ± 0.06
Table 4.1: Percentage of ALDH+ cells obtained from enriched
ALDH+ and ALDH- cell population after 14 days of culture. ALDH
positive and negative cells sorted from MCF-7/TamR and MCF-
7/ADR were cultured in monolayer for 14 days. ALDH activity was
determined using Aldefluor assay. *mean ± S.D. of three indepen-
dent experiments.
selective media on low attachment plates, an in vitro characteristic of TICs
[116, 132]. The ALDH+ populations from MCF-7/TamR and MCF-7/ADR
cell lines, seeded at 15-2,000 and 250-4,000 ALDH+ cells, formed significantly
more mammospheres in comparison with ALDH- and unsorted cells (Fig 4.2A
and B). 500 seeded ALDH+ MCF-7/TamR cells and 4,000 seeded ALDH+
MCF-7/ADR cells demonstrated a 18.4 and 17.6 fold increase in their ability
to form mammospheres compared to ALDH- cells seeded at the same cell con-
centration, respectively (Fig 4.2 A and B), indicating that TICs are enriched
in ALDH+ populations in both cell lines. In the colony formation assay, the
number of colonies formed by ALDH+ cells from MCF-7/TamR and MCF-
7/ADR cell lines, seeded at 100, 200, and 400 cells/plate were significantly
higher than the ALDH- cells treated in a like manner (Fig 4.2 C and D). The
ALDH+ cells showed a 5.4 and 4.2 fold increase in colony formation compared
to the ALDH- cells (Fig 4.2 C and D), respectively.
Furthermore, to determine if the FACS sorted ALDH+ cells undergo
differentiation, ALDH+ enriched cells from MCF-7/TamR and MCF-7/ADR
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cells were seeded in monolayer culture plates and cultured for two weeks, cells
harvested and re-sorted on the basis of ALDH+. The number of ALDH+ cells
for MCF-7/TamR and MCF-7/ADR cell lines were 6.03 0.47% and 6.3 0.78%,
respectively (Table 4.1), approximately the same percentage of ALDH+ cells
observed in unsorted cell lines (Fig 4.1 A). These data suggest, as previously
reported [111, 181], that ALDH+ enriched cells grown in monolayer cultures
for two weeks give rise to ALDH- cells and maintain the original ALDH+
percentage. No increase in ALDH+ cells was observed when ALDH- cells were
cultured under the same conditions. Furthermore, these experiments show
that ALDH- cell populations, under these conditions, do not have the capacity
to revert to ALDH+ cells. These observations provide further evidence that
TICs are enriched in ALDH+ populations in these drug-resistant human breast
cancer cell lines.
4.4.3 Unsorted MCF-7/TamR andMCF-7/ADR breast cancer cells
express high levels of phosphorylated (active) signal trans-
ducer and activator of transcription-3 (pStat-3), which is en-
riched in the ALDH+ sorted cell population.
To better understand the mechanisms by which TICs are maintained
at the enriched levels in MCF-7/TamR and MCF-7/ADR cell lines, western
blot analyses were conducted using unsorted cell extracts from the two drug
resistant cell lines and their respective parental cell lines to determine protein
levels of pStat-3, cyclin D1, transcription factor c-Myc, Bcl-2 family mem-
ber Bcl-xL, and Survivin. All of these factors which are associated with cell
division and cell survival were highly expressed in the drug resistant cells in
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comparison to their parental counterparts (Fig 4.3A). Additional western blot
analyses were conducted to determine levels of pStat-3 and downstream media-
tors in MCF-7/TamR and MCF-7/ADR ALDH+ enriched cells in comparison
to ALDH- and unsorted cells. The ALDH+ population had higher protein
levels of pStat-3 (Tyr-705), Cyclin D1, c-Myc, Bcl-xL and Survivin in compar-
ison with ALDH- and unsorted populations in both drug resistant cell lines
(Fig 4.3B), suggesting pStat-3 involvement in TIC proliferation and survival.
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Figure 4.2: Mammosphere formation assay was performed using
sorted ALDH+, ALDH- and unsorted cells (A and B). Colony for-
mation assay was performed using ALDH+ and ALDH- cells(C and
D). The numbers of mammospheres (A and B) or colonies (C and
D) are presented as means ± SD of three individual experiments.
*significantly different from ALDH- or unsorted cells, p < 0.05.
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Figure 4.3: Drug resistant breast cancer cells express higher levels
of pStat-3, which is enriched in ALDH+ population.Western blot
analyses were performed to determine protein expression in unsorted
population in comparison with their parental cell lines using GAPDH
as loading control (A) and in ALDH+ population in comparison with
unsorted and ALDH- populations using GAPDH as loading control
(B). Data are representative of two or more independent experiments.
4.4.4 The Stat-3 signalling pathway is critical for maintaining TIC
enriched populations in drug resistant breast cancer cells.
Rationale for focusing the mechanistic studies on Stat-3 comes from
a study showing Stat-3 to be important for maintenance of TICs in MCF-7
breast cancer cells [182]. In order to determine if Stat-3 contributes to main-
tenance of TIC-enriched populations in our drug resistant cell lines, we used
the mammosphere assay as a measure for number of TICs following inhibi-
tion of Stat-3 activity with the chemical inhibitor. Cucurbitacin I is a potent
inhibitor of the janus kinase 2/Stat-3 signaling pathway which exhibits anti-
tumor and anti-proliferative properties (Sigma Aldrich.com). Stat-3 inhibitor
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MCF-7/TamR MCF-7/ADR
ALDH+ CD44+/CD24- ALDH+ CD44+/CD24-
VEH 6.03 ± 0.30 55.75 ± 0.20 5.60 ± 0.65 28.12 ± 1.67
JSI-124 (0.125 µM) 0.37 ± 0.29* 30.35 ± 5.90* 0.45 ± 0.32* 5.01 ± 2.55*
Table 4.2: Effect of Stat3 inhibitor on TIC population. MCF-
7/TamR and MCF-7/ADR were treated with vehicle control or
with JSI-124 (0.125M) for 2 days followed by determination of
ALDH+ and CD44+/CD24- populations using ALDH activity and
CD44+/CD24- immunostaining assays, respectively. *significantly
different from vehicle (VEH), p < 0.05 using students t-test. Mean
± S.D. of three independent experiments
significantly reduced the number of mammospheres in a dose-dependent man-
ner in both drug resistant cell lines (Fig 4.4A). Stat-3 inhibitor also signif-
icantly reduced the ALDH+ and CD44+/CD24- populations in both drug
resistant cell lines (Table 4.2).
Furthermore, western blot analyses show that Stat-3 inhibitor sup-
pressed protein levels of pStat-3 (Tyr-705), as well as Cyclin D1, c-Myc, Bcl-xL
and Survivin (Fig 4.4 B), suggesting that Cyclin D1, c-Myc, Bcl-xL and Sur-
vivin are downstream mediators of Stat3. Taken together, these data demon-
strate a critical role for Stat-3 in TIC survival. Since CyclinD1, c-Myc, Bcl-xL
and Survivin are established stem cell mediators [183, 184], our data suggest
that high expression of active Stat-3 (pStat-3, Tyr-705) is necessary but not
totally sufficient for maintenance of TIC populations in drug resistant cells.
91
Figure 4.4: Stat-3 is critical for maintaining TIC enriched popula-
tions in drug resistant cells.ALDH+ populations were treated with
indicated concentrations of STAT-3 inhibitor for 7 days to determine
the number of mammospheres as detected by mammospheres forma-
tion assay (A). Western blot analyses were performed to evaluate
protein expression in unsorted DR cells treated with Stat-3 inhibitor
or VEH control for 2 days (B). Data are representative of two or
more independent experiments. Data are presented as means SD
of three individual experiments. *significantly different from VEH,
p < 0.05.
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4.4.5 Both SVA and γT3 reduce TICs and suppress pStat-3(Tyr-
705), CyclinD1, c-Myc, Bcl-xL, and Survivin protein expres-
sion in both drug resistant human breast cancer cell lines.
The ability of SVA and γT3 to reduce TICs was evaluated by ALDH
activity assay, staining for CD44+/CD24- and mammosphere formation of
ALDH+ populations. Treatment of MCF-7/TamR and MCF-7/ADR cells
with increasing levels of SVA or γT3 for 2 days significantly reduced the per-
centages of ALDH+, CD44+/CD24- and ALDH+/CD44+/CD24- populations
in a dose-dependent manner (Fig 4.5 A, B and C). SVA at 2.5 µM or less and
γT3 at 5 µM or less are pharmacologically achievable levels [138, 185], thus,
these data show that SVA as well as γT3 at pharmacologically achievable
levels levels eliminate TICs in drug resistant cell populations. Furthermore,
treatment of ALDH+ cells obtained from MCF-7/TamR and MCF-7/ADR
cells with pharmacologically achievable levels of SVA or γT3 for 1 week sig-
nificantly reduced the number of mammospheres formed in a dose-dependent
manner (Fig 4.5 D). These data demonstrated that SVA as well as γT3 re-
duces the number of TICs in drug resistant breast cancer cells. Both SVA
and γT3 at pharmacologically achievable levels suppressed pStat-3(Tyr-705),
CyclinD1, and c-Myc, Bcl-xL and Survivin protein levels in a dose-dependent
manner in unsorted MCF-7/TamR and MCF-7/ADR cell lines (Fig 4.5 E).
Furthermore, treatment of ALDH+ cells sorted from MCF-7/TamR or MCF-
7/ADR cell lines with SVA at 0.625µM or γT3 at 7.5µM suppressed pStat-3
(Tyr-705) , CyclinD1, c-Myc, Bcl-xL and Survivin protein levels (Fig 4.5 F).
These data suggest that downregulation of these TIC-associated mediators
maybe important in SVA or γT3 mediated elimination of TICs.
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Figure 4.5: A and B
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Figure 4.5: C and D
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Figure 4.5: γT3 and SVA abolishes characteristics of TICs and
suppresses pStat-3, c-Myc, Cyclin D1, Bcl-xL and Survivin protein
expression in DR breast cancer cells.Unsorted cells were treated with
indicated concentrations of γT3 and SVA for 2 days to determine
ALDH+ population as detected by ALDH activity assay (A), to de-
termine CD44+/CD24- population as detected by immune-staining
assay (B) and ALDH+/CD44+/CD24- populations(C). ALDH+
populations were treated with indicated concentrations of γT3 and
SVA for 7 days to determine the number of mammospheres as de-
tected by mammospheres formation assay (D). Data are presented
as means ± SD of three individual experiments. *significantly dif-
ferent from VEH, p < 0.05. Western blot analyses were performed
to evaluate protein expression in unsorted cells treated with different
concentrations of γT3 and SVA or VEH control for 2 days (E) and
in ALDH+ enriched cells treated with γT3 at 7.5 µM and SVA at
0.625 µM or VEH control for 2 days (F). Data are representative of
two or more independent experiments.
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4.4.6 Combination of SVA and γT3 act cooperatively to reduce
ALDH+ cells, and to suppress pStat-3(Tyr-705), Cyclin D1,
c-Myc, Bcl-xL and Survivin protein levels in drug resistant
breast cancer cells.
Since both SVA and γT3 as exhibit low bioavailability in vivo [177],
combinations of low doses of SVA and γT3 that have been reported to be
achievable in vivo [177] were studied in an effort to improve the anti-TIC ef-
ficacy, in comparison to single treatments. MCF-7/TamR and MCF-7/ADR
cells were cultured with the combination of SVA (0.625 µM) and γT3 (5 µM)
for 2 days. In comparison to single treatments, the combination of SVA plus
γT3 significantly decreased ALDH+, CD44+/CD24- and ALDH+/CD44+/CD24-
populations in both cell lines (Fig 4.6 A, B and C), and significantly reduced
mammosphere formation (Fig 4.6 D). The combination of SVA and γT3 at
low concentrations suppressed pStat-3(Tyr-705), Cyclin D1, and c-Myc pro-
tein levels in comparison to vehicle control and single treatments in both cell
lines (Fig 4.6 E). Furthermore, SVA + γT3 treatment of ALDH+ cell popula-
tions from both cell lines acted cooperatively, in comparison to vehicle control,
to suppress pStat-3(Tyr-705), CyclinD1, c-Myc, Bcl-xL and Survivin protein
levels in ALDH+ population (Fig 4.6 F).
4.4.7 SVA and γT3 alone and in combination eliminate bulk drug
resistant breast cancer cells via apoptosis.
Previous data showed that the combination of SVA + γT3 coopera-
tively induce apoptosis in mammary cancer cells [177], suggesting potential for
this combination for breast cancer treatment. Since both of the drug resistant
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cell lines used in these studies are resistant to chemotherapeutic agent-induced
apoptosis; namely, ADR and cisplatin (data not shown) and tamoxifen [133],
it is important to identify anti-cancer agents that can eliminate drug resistant
bulk cancer cells. Therefore, the anticancer properties of SVA and γT3 alone
and in combination were studied for ability to induce apoptosis in both drug
resistant cell lines.
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Figure 4.6: Combination of γT3 and SVA cooperatively eliminates
TICs and suppress pStat-3, c-Myc, Cyclin D1, Bcl-xL and Survivin
protein expression in DR breast cancer cells.Cells were treated with
combination of γT3 and SVA for 2 days followed by ALDH activity
assay (A), CD44/CD24 immuno-staining assay (B) and both assays
(C). ALDH + cells were treated with combination of γT3 and SVA
for 1 week for mammosphere formation assay (D). Western blot anal-
yses were performed to evaluate protein expression in unsorted cells
treated with γT3 at 5 µM and SVA at 0.625 µM or VEH control for
2 days and in ALDH+ enriched cells treated with γT3 at 2.5 µM and
SVA at 0.3125 µM (E and F). Data from E and F are representative
of two or more independent experiments. Data from A, B, C and D
are presented as the mean ± S.D. of three independent experiments.
*significantly reduced in comparison to Vehicle, p < 0.05.
Treatments of MCF-7/TamR and MCF-7/ADR cells with different con-
centrations of SVA or γT3 alone for 2 days significantly induced apoptosis in
a dose response manner (Fig 4.7 A and B) and PARP cleavage, an indicator
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of caspase dependent apoptosis (Fig 4.7 E). The combination of sub-apoptotic
doses of SVA (0.625 µM) + γT3 (5 µM) significantly induced apoptosis, in
comparison to SVA and γT3 alone, in both drug resistant cell lines (Fig 4.7
C, D and F). Furthermore, SVA and γT3 alone induced increased cleavage of
caspases-8 and -9 (Fig 4.7 E). The combination of sub-apoptotic doses of SVA
+ γT3, in comparison to single treatments, enhanced cleavage of caspases 8
and 9 (Fig 4.7 F), suggesting involvement of death receptor- and mitochondria-
mediated apoptotic pathway.
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Figure 4.7: γT3 and SVA alone and in combination target bulk of
drug resistant breast cancer cells by inducing apoptosis. Cells were
treated with various concentrations of γT3 and SVA alone (A and
B) or in combination of γT3 + SVA (C and D) for 2 days followed
by Annexin V assay to determine apoptosis. Western blot analyses
were performed to evaluate cleavage of PARP, caspase-8 and -9 (E
and F). Data from E and F are representative of two or more inde-
pendent experiments. Data from A, B, C and D data are presented
as the mean ± S.D. of three independent experiments. *significantly
reduced in comparison to Vehicle, p < 0.05. * significantly reduced
in comparison to single treatments, p < 0.05.
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4.4.8 SVA and γT3 alone and in combination activate JNK/CHOP/DR5
pro-apoptotic pathway.
Previous studies showed that SVA and γT3 alone induced apoptosis
in human breast cancer cells, including MCF-7 cells, via activation of JNK,
CHOP and DR5 [32] [submitted data]. Treatment of MCF-7/TamR and MCF-
7/ADR cells with different concentrations of SVA or γT3 for 2 days increased
pJNK (2/1), CHOP, DR5, and GRP78 protein levels (Fig 4.8 A). A com-
bination of sub-apoptotic doses of SVA + γT3, in comparison with single
treatments, acted cooperatively to enhance these pro-apoptotic proteins (Fig
4.8 B). These data suggest that both SVA and γT3 alone and in combination
induce apoptosis in drug resistant cells via activation of JNK/CHOP/DR5
pro-apoptotic pathway.
4.5 Discussion
Both SVA and γT3 alone and in combination exhibit anticancer actions
in vitro and in vivo [52–54, 124]. In this study we evaluated their anticancer ac-
tion on eliminating TICs in tamoxifen and adriamycin resistant human breast
cancer cell lines. The novel findings of this study are: (i) Like MCF-7/ADR
cells [132], MCF-7/TamR cells are enriched in TICs in comparison to the
parental cell line, (ii) Both drug-resistant cell lines express higher levels of
pStat-3, c-Myc, CyclinD1, Bcl-xL and Survivin than parental lines and these
pro-proliferation/survival factors are concentrated in TIC enriched cells, (iii)
expression of phosphorylated Stat-3 contributes to increased numbers of TICs
in drug resistant cell lines, (iv) SVA and γT3 eliminated TICs as well as sup-
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Figure 4.8: γT3 and SVA alone and in combination induce ac-
tivation of JNK/CHOP/DR5 pro-apoptotic pathway.Western blot
analyses were performed to evaluate protein expression. Data are
representative of two or more independent experiments.
pressed protein expression of Stat-3, c-Myc, CyclinD1, Bcl-xL and Survivin in
both cancer bulk and TIC cell populations, and (v) both SVA and γT3 alone in-
duce apoptosis in these two drug resistant cell lines which is associated with ac-
tivation of the JNK/CHOP/DR5 pro-apoptotic pathway and the combination
of SVA + γT3 cooperatively enhanced these anticancer events. Taken together,
our data demonstrated that SVA and γT3 alone and in combination at phar-
macologically achievable doses exhibit the ability to target both TIC-enriched
and TIC depleted cell populations in drug resistant breast cancer cell lines,
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suggesting that the combination of SVA and γT3 may be a potential strategy
for prevention and treatment of drug resistant breast cancer by targeting both
TIC-enriched and non-TIC cells. Data also provide evidence that Stat-3 may
be a novel target for prevention and treatment of drug resistant breast cancer
via enhanced elimination of TIC-enriched populations. Based on the cancer
stem cell concept, targeting TICs provide a new hope for eradicating cancers,
including breast cancer. Accumulating evidence support the observations that
traditional cancer therapies such as chemotherapeutic agents and radiation
therapy specifically target non-TICs/bulk of the tumor cells, leaving behind
the more resistant TIC populations which can generate tumors. Several lines of
in vitro and textitin vivo data show that conventional therapies enrich for TICs
[112, 116, 186] thus, leading to tumor recurrence, drug resistance and metas-
tasis. These may explain why current therapies are incapable of eradicating
cancer. Based on the cancer stem cell concept, targeting TICs holds promise
for prevention and treatment of drug resistance.cancer statistics Therefore, the
finding that drug resistant cells contain a higher percentage of TIC-enriched
cells supports the TIC concept that drug resistant cancers become more aggres-
sive, metastatic and treatment resistant due to selection of TIC population.
Previously, Calcagno AM, et al. reported that in comparison to parental cells,
MCF-7/ADR cells (the same cell line used in this study) were highly invasive,
formed mammospheres and contain higher percentage of CD44+/CD24- cells
in vitro which resulted in higher tumorigenicity textitin vivo [132]. Their data
indicated that cells possessing cancer stem cell characteristics were enriched
in the MCF-7/ADR cell line in comparison to the parental cell line [132].
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Although acquired MCF-7/TamR cells have been shown to exhibit an EMT
phenotype [112, 173], there are no published data supporting that TICs are
enriched in TamR cells. Calcagno AM, et al. also reported that the MCF-
7/ADR cells were enriched in ALDH+ cells but it was not confirmed to be
a TIC marker like seen in SUM159 human breast cancer cells [109]. Here,
our data demonstrate that both resistant cell lines contain higher levels of
ALDH+ cells, and that cells enriched for ALDH+ exhibit cancer stem cell
characteristics; namely, formation of greater numbers of mammospheres (Fig-
ure 2A) in comparison with ALDH- populations in both drug resistant cell
lines, and ability to differentiate into ALDH- cells (Table1). In addition, both
cell lines contain higher levels of CD44+/CD24- populations. CD44+/CD24-
has been identified as a TIC marker in multiple breast cancer cell lines and
tumors [113] but they do not always represent a true TIC population. How-
ever the CD44+/CD24- phenotype has been challenged as a biomarker for
TICs by some [187]. CD44+/CD24- populations have been studied as a TIC
marker in regular MCF-7 cells [188] and Calcagno AM, et al. reported that the
CD44+/CD24- population in MCF-7/ADR exhibits TIC characteristics such
as self-renewal and tumor initiation [132]. Croker AK, et al. reported that
the ALDH+/CD44+/CD24- population is more enriched for TIC as well as
chemotherapy and radiation resistance in MDA-MB-231 cells [180, 187]. Based
on these studies, we examined the expression of ALDH+/CD44+/CD24- pop-
ulations in both drug sensitive and drug resistant cell lines. In comparison
with their parental cell lines, both MCF-7/TamR and MCF-7/ADR cell lines
not only expressed higher percentage of ALDH+, CD44+/CD24-, but also
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ALDH+/CD44+/CD24- populations. Taken together, our data demonstrate
that MCF-7/TamR and MCF-7/ADR contain higher levels of TIC-enriched
populations. TICs are regulated by multiple mediators, including Wnt/beta-
catenin, PI3K/PTEN/mTOR/AKT, Notch, Hedgehog, NF- κB, Her-2 and
Stat-3 [107, 182]. However, the factors that regulate TICs in drug-resistant
breast cancer have not been well addressed. Over-expression of growth fac-
tor receptor signaling pathway in MCF-7/TamR cells is well documented [133].
Data also show that NF- κB, Stat-3, Akt, and ERK are highly expressed in this
cell line [133][unpublished data]. On the other hand, MCF-7/ADR cell line has
been reported to express high levels of multiple drug resistant (MDR) and NF
κB proteins [189]. Furthermore, we observed that pERK, pStat-3 and pIκB,
but not pAkt, are over-expressed in MCF-7/ADR compared to the parental
cell line (Fig 3A, unpublished data). By characterizing the molecular profile
we found that overexpression of pStat-3 (Tyr-705), c-Myc, CyclinD1, Bcl-xL
and Survivin is a common event for both drug resistant cell lines. Importantly,
these signaling events are more highly elevated in TIC enriched populations
in comparison with TIC-depleted and unsorted populations. Stat-3 has been
reported to mediate TICs in MCF-7 cells [182] and contributes to maintenance
of TIC in vivo as well [122]. In agreement with these data, our data show that
knockdown of Stat-3 using Stat-3 inhibitor eliminated TIC-enriched popula-
tions in both drug resistant cell lines and thus support the role of Stat-3 in
regulating TICs of drug resistant breast cancer cells. These important findings
suggest that Stat-3 may be an important target for eliminating TICs in drug
resistant human breast cancers irrespective of the origin of resistance. c-Myc,
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CyclinD1, Bcl-xL and Survivin are established stem cell mediators [183, 184]
and can be regulated by different pathways, such as growth factor receptor
mediated Akt, NF-κB and Stat3 [190–192]. Our data showing that a Stat-3
inhibitor reduced c-Myc, CyclinD1, Bcl-xL and Survivin protein expression,
suggests that Stat-3 is an upstream mediator of these factors in these two drug
resistant cell lines. One of the novel findings in this study is that SVA and
γT3 alone or in combination eliminate TIC-enriched population as demon-
strated by treatment: (i) elimination of ALDH+ population, (ii) reduction
in CD44+/CD24- cell numbers as well as ALDH+/CD44+/CD24- numbers,
and (iii) inhibition of mammosphere formation by ALDH+ population. Fur-
thermore, our data show that SVA and γT3 alone or in combination inhibited
pStat-3 as well as c-Myc and CyclinD1 protein expression. Since our data
suggest that Stat-3 is involved in regulating TICs in both drug resistant cell
lines, we hypothesized that downregulation of Stat-3 and its downstream me-
diators c-Myc, CyclinD1, Bcl-xL and Survivin contribute to the ability of the
treatments to eliminate TICs in drug resistant cell lines. Stat-3 is a tran-
scription factor and has been reported to be regulated mainly by JAK and
Src mediated activation of NF-κB/IL-6 [193]. Also, SHP-1, a tyrosine phos-
phatase, can negatively regulate Stat-3 via dephosphorylation of pStat-3 at
Tyr-705 [39]. Both SVA and γT3 alone have been reported to downregulate
pStat-3 [111, 179]. γT3 has been reported to downregulate pStat-3 via up-
regulation of SHP-1 [179]. Our unpublished data show that both SVA and
γT3 alone and in combination induced increased levels of SHP-1 (Data not
shown). Since both SVA and γT3 have been reported to downregulate NF-κB
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[52, 185], it is possible that both downregulation of NF-κB and upregulation
of SHP-1 contribute to SVA and γT3 suppression of Stat-3. Proof of NF-
κB and SHP-1 involvement remain to be tested. Pro-apoptotic properties of
SVA and γT3 alone and in combination have been reported in different can-
cer types, including breast cancer cells [32, 50–54, 177, 194]. However, to the
best of our knowledge, this is the first report that SVA and γT3 alone or
in combination induce apoptosis in drug resistant cell lines. It is important
to develop strategies to effectively kill drug resistant cancer cells since over-
time they develop cross-resistance to multiple anticancer treatments [2]. For
example; MCF-7/ADR cells are resistant to tamoxifen due to down regula-
tion of estrogen receptor expression and cells exhibit resistance to cisplatin
(unpublished data) [133]. Likewise MCF-7/TamR cells exhibit greater resis-
tance both to doxorubicin and cisplatin possibly due to the high expression of
multiple anti-apoptotic factors [32][unpublished data]. Furthermore, previous
data show that JNK/CHOP/DR5 are activated and involved in both SVA-
and γT3-induced apoptosis in MCF-7 cells [32] [submitted manuscript]. In
agreement with these data SVA and γT3 alone activated JNK, CHOP and
DR5 pro-apoptotic mediators in these drug resistant breast cancer cells, sug-
gesting that JNK/CHOP/DR5 pro-apoptotic pathway contribute to SVA- and
γT3- induced apoptosis. Although the combination of SVA + γT3 has been
reported previously to cooperatively induce apoptosis, the underlining mecha-
nism was not addressed [177]. Here, we report that the combination of SVA +
γT3 cooperatively induces activation of JNK/CHOP/DR5. Despite the fact
that SVA and γT3 alone exhibit both anti-TIC and anti non-TIC properties,
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the combination effect of lower doses of SVA + γT3 on TICs and non-TICs
elimination may be more clinically relevant based on bioavailability and less
toxicity. For example, the in vivo concentrations of SVA of 2 µM have been
associated with multiple toxic side effects [138]. Hence, the combination strat-
egy provides an opportunity to use less toxic concentrations without sacrificing
treatment efficacy. In summary, our data demonstrate that two different drug
resistant human breast cancer cell lines contain higher levels of TIC enriched
populations that in part are maintained via highly expressed phosphorylated
Stat-3 and its downstream mediators c-Myc, CyclinD1, Bcl-xL and Survivin,
and that SVA and γT3 target TICs via suppression of phosphorylated Stat-3
and its downstream mediators c-Myc, CyclinD1, Bcl-xL and Survivin. Data
provide new insights into how TICs are regulated in drug resistant breast can-
cer cells and suggest the potential for the combination of SVA + γT3 as a
novel regimen for prevention and treatment of drug resistant breast cancer via
targeting TICs and bulk tumor cells. Data also suggest that phosphorylated
Stat-3 is a potential target for elimination of TICs in drug resistant breast




Summary and future directions
5.1 Conclusion
γT, γT3 and SVA have been reported to display anticancer properties
against multiple types of cancer both in cell culture and in pre-clinical animal
models, providing support for the use of γT, γT3 and SVA as anticancer ther-
apeutics yet the mechanisms involved in these actions remain elusive. Studies
here, focused on identifying mechanisms involved in anticancer effects medi-
ated by two natural forms of vitamin E γT and γT3; as well as, simvastatin
in human breast cancer cells. Briefly, γT and γT3 were observed to induce
apoptosis via activation of de novo ceramide pathways leading to upregula-
tion of proapoptotic JNK/CHOP/DR5 and downregulation of c-FLIP, Bcl-2
and Survivin. SVA mediated apoptosis was observed to involve activation of
proapoptotic JNK/CHOP/DR5 axis where JNK/CHOP were in part respon-
sible for SVA mediated downregulation of c-FLIP and Survivin. Furthermore,
γT3 and SVA alone and in combination were demonstrated to target TIC
populations in drug resistant breast cancer cells. In summary, these studies
improved our present understanding and provide key insights that will benefit
future studies aimed at using these agents as therapeutics for breast cancer in
human.
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Chapter 2 studies determined downstream mediators of apoptosis in
SVA treated human breast cancer cells. Work done by Koyuturk M et al, 2007
demonstrated that JNK is involved in SVA induced apoptosis but factors and
process from JNK activation to actual induction of apoptosis were unknown.
Work here shows that SVA induced prolonged phosphorylation of JNK leading
to apoptosis via downstream activation of CHOP and DR5. Simultaneously,
SVA-induced apoptosis is accompanied by downregulation of antiapoptotic fac-
tors c-FLIP and Survivin which are in part dependent on JNK/CHOP/DR5
proapoptotic axis. Exogeneously added mevalonate or geranylgeranyl py-
rophosphate (GGPP) blocked SVA-induced activation of JNK/CHOP medi-
ated apoptosis and downregulation of c-FLIP and Survivin. These novel find-
ings provide insights into the critical events involved in SVA-induced apoptosis
in human breast cancer cells.
Chapter 3 compared events common to both γT and γT3 induced apop-
tosis. Studies also helped identify the upstream mediators of γT induced acti-
vation of DR5 in human breast cancer cells. Similar to γT3, γT induced DR5
activation was observed to involve upstream activation of JNK and CHOP
and was accompanied by activation of endoplasmic reticulum stress. Another
finding here is the dependence of downregulation of antiapoptotic factors by
γT on JNK/CHOP/DR5 proapoptotic loop. In addition, both forms of vita-
min E were observed to initiate de novo ceramide synthesis prior to activation
JNK/CHOP/DR5, apoptosis, and downregulation of antiapoptotic factors.
These finding demonstrate that γT induces apoptosis via activation of similar
upstream mediators like γT3 and apoptosis induced by both forms of vitamin
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E involve activation of the de novo ceramide pathway.
Chapter 4 characterized the molecular differences between drug- sensi-
tive and -resistant human breast cancer cells. Increased expression of signal
transducer and activator of transcription 3 (Stat3) has been correlated with
invasive malignant tissue compared to surrounding normal tissue in breast can-
cer (Diaz et al 2006) but there is no evidence in the literature for the role of
Stat3 in drug resistance and regulation of TICs in drug resistant breast cancer
[195]. Work here shows that both forms of drug resistant breast cancer cells
express higher levels of TIC populations and phosphorylated Stat3 as well as
its downstream mediators c-Myc, cyclinD1, Bcl-xL and Survivin compared to
their drug sensitive parental counterparts. Inhibition of Stat3, demonstrated
a role for Stat3 in maintenance of TICs in drug resistant breast cancer. More-
over, γT3, SVA and combination of γT3+SVA were observed to target the
over expressed Stat3 pathway and TICs in drug resistant cells. Hence, devel-
opment of drug resistance in human breast cancer is associated with increased
expression of Stat3 and TICs which can be counteracted by γT3, SVA or the
combination of γT3+SVA treatments.
5.2 Future Directions
During the course of this study, multiple questions were raised which
need to be addressed in future studies to gain a more complete understand-
ing of mechanisms involved in γT, γT3 and SVA mediated anticancer effects.
Firstly, previous studies have shown that γT induced activation of Peroxisome
proliferator-activated receptor gamma (PPARγ) receptors which may play an
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important role in apoptosis and proliferation but there is no evidence in the
literature investigating the interrelationship between induction of PPARγ ac-
tivation with de novo ceramide synthesis in γT treatments [196]. Although
PPARγ has been shown to activated by C2-ceramide in human colon ade-
nocarcinoma, there is no evidence in literature to show if these pathways are
connected[197], further studies will have to be carried out to determine if these
events occur in a sequence: namely does there exists any cross-talk between
these two pathways? Or is the activation of these pathways independent si-
multaneously occurring events in γT induced apoptosis?
Secondly, it is necessary to test the tumor initiating property of ALDH
enriched versus ALDH depleted cells in vivo in NOD/SCID mice. Thus, pro-
viding proof of principle for existence of TIC populations in ALDH enriched
subpopulation and lending further support to the already obtained in vitro
data. Furthermore the effect of orally administered SVA and γT3 in combi-
nation for its ability to target TIC populations has to be tested in vivo in
NOD/SCID mice.
Thirdly, there is evidence in the literature that γT3 induced apopto-
sis is accompanied by activation of protein tyrosine phosphatase SHP-1 and
suppression of Stat3 and NFκB pathways [38, 39]. It would be of interest to
determine if activation of JNK/CHOP/DR5 axis is responsible for downreg-
ulation of transcription factors, Stat3 and NFκB or if these are independent
events that occur during γT3 treatment. Such studies help in the development
of multiple biomarkers for identification of γT3 treatment efficacy to be used
in clinical assessments.
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Fourthly, Stat3 has been shown in the literature to be regulated by
SHP-1 and NFκB [39, 193]. Furthermore, γT3 and SVA have been shown in
the literature to downregulate NFκB in human breast cancer cells [52, 185].
In this work, for the first time, a role for Stat3 in the development of drug
resistance and TICs was demonstrated. Also, SVA was observed to enhance
SHP-1 in a dose dependent manner and drug resistant cells expressed lower
levels of SHP-1 protein compared to the parental cells (Figure 5.1 A and B).
Hence, there is a need to determine if SHP-1+NFκB or if one or the other of
these factors can regulate Stat3 in drug resistant breast cancer and if so do
they play a role in SVA or γT3+SVA mediated anti-TIC effects.
Figure 5.1: SHP-1 regulation in drug resistant cells.
SHP-1 regulation in drug resistant cells.Western blot analyses of
MCF-7/TamS, MCF-7/TamR, MCF-7 and MCF-7/ADR untreated
or treated with indicated concentrations of γT3 and SVA for 48
hours. GAPDH was used as loading control. Data representative
of at least three independent experiments.
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